WO2023220833A1 - Combined inhibition of tyrosine phosphatases tcptp and ptp1b and pd-1 blockage immunotherapy in the treatment of cancer - Google Patents
Combined inhibition of tyrosine phosphatases tcptp and ptp1b and pd-1 blockage immunotherapy in the treatment of cancer Download PDFInfo
- Publication number
- WO2023220833A1 WO2023220833A1 PCT/CA2023/050693 CA2023050693W WO2023220833A1 WO 2023220833 A1 WO2023220833 A1 WO 2023220833A1 CA 2023050693 W CA2023050693 W CA 2023050693W WO 2023220833 A1 WO2023220833 A1 WO 2023220833A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- halogens
- alkyl
- group
- aryl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 59
- 238000011282 treatment Methods 0.000 title claims abstract description 48
- 201000011510 cancer Diseases 0.000 title claims abstract description 38
- 230000005764 inhibitory process Effects 0.000 title description 15
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 title description 11
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 title description 10
- 238000009169 immunotherapy Methods 0.000 title description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 130
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims abstract description 53
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims abstract description 53
- 150000003839 salts Chemical class 0.000 claims abstract description 53
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims abstract description 51
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 40
- 150000002367 halogens Chemical class 0.000 claims description 597
- 229910052736 halogen Inorganic materials 0.000 claims description 588
- 125000000217 alkyl group Chemical group 0.000 claims description 360
- 125000003118 aryl group Chemical group 0.000 claims description 195
- 125000001072 heteroaryl group Chemical group 0.000 claims description 194
- 125000001424 substituent group Chemical group 0.000 claims description 113
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 61
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 55
- 125000001188 haloalkyl group Chemical group 0.000 claims description 52
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 33
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 31
- -1 (iii) -(C=O)OH Chemical group 0.000 claims description 31
- 230000002601 intratumoral effect Effects 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 29
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 25
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 235000019000 fluorine Nutrition 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 13
- 125000004437 phosphorous atom Chemical group 0.000 claims description 13
- 229910052698 phosphorus Inorganic materials 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 238000007910 systemic administration Methods 0.000 claims description 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 10
- NCEMUOYFYLEORV-UHFFFAOYSA-N difluoromethylphosphonic acid Chemical compound OP(O)(=O)C(F)F NCEMUOYFYLEORV-UHFFFAOYSA-N 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims description 8
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 229950009791 durvalumab Drugs 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 229960003852 atezolizumab Drugs 0.000 claims description 4
- 229950002916 avelumab Drugs 0.000 claims description 4
- 229950007712 camrelizumab Drugs 0.000 claims description 4
- 229940121420 cemiplimab Drugs 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 229940121432 dostarlimab Drugs 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 229950010773 pidilizumab Drugs 0.000 claims description 4
- 229940121497 sintilimab Drugs 0.000 claims description 4
- 229950007213 spartalizumab Drugs 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 230000002992 thymic effect Effects 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 229950007123 tislelizumab Drugs 0.000 claims description 4
- 229940121514 toripalimab Drugs 0.000 claims description 4
- 229950007217 tremelimumab Drugs 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 110
- 210000004027 cell Anatomy 0.000 description 107
- 230000014509 gene expression Effects 0.000 description 59
- 101100522280 Dictyostelium discoideum ptpA1-2 gene Proteins 0.000 description 56
- 101150006497 PTP-1 gene Proteins 0.000 description 56
- 108090000623 proteins and genes Proteins 0.000 description 47
- 239000012636 effector Substances 0.000 description 38
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 33
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 31
- 241000699670 Mus sp. Species 0.000 description 31
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 30
- 230000002950 deficient Effects 0.000 description 30
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 27
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 26
- 230000004069 differentiation Effects 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 21
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 20
- 102100033467 L-selectin Human genes 0.000 description 20
- 230000026731 phosphorylation Effects 0.000 description 20
- 238000006366 phosphorylation reaction Methods 0.000 description 20
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 19
- 230000028327 secretion Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 102100032912 CD44 antigen Human genes 0.000 description 15
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 15
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 108090000174 Interleukin-10 Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 238000003119 immunoblot Methods 0.000 description 13
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 102000040945 Transcription factor Human genes 0.000 description 12
- 108091023040 Transcription factor Proteins 0.000 description 12
- 238000012217 deletion Methods 0.000 description 12
- 230000037430 deletion Effects 0.000 description 12
- 238000011740 C57BL/6 mouse Methods 0.000 description 11
- 230000001472 cytotoxic effect Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 10
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 10
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 10
- 210000001165 lymph node Anatomy 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 9
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 208000008732 thymoma Diseases 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 101001135572 Homo sapiens Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 108010015832 Non-Receptor Type 2 Protein Tyrosine Phosphatase Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000024245 cell differentiation Effects 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 230000009038 pharmacological inhibition Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 description 5
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 5
- 102000002227 Interferon Type I Human genes 0.000 description 5
- 108010014726 Interferon Type I Proteins 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 5
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000001461 cytolytic effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000008482 dysregulation Effects 0.000 description 5
- 210000003162 effector t lymphocyte Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102100030751 Eomesodermin homolog Human genes 0.000 description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 4
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 4
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 101150001354 Ptpn2 gene Proteins 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000006023 anti-tumor response Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000005746 immune checkpoint blockade Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108091008042 inhibitory receptors Proteins 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008093 supporting effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo[3.3.1]nonane Substances C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 101000903609 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 3 Proteins 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 101100369641 Mus musculus Tigit gene Proteins 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 108091008638 NR4A Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 3
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 3
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 3
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- JPMOKRWIYQGMJL-UHFFFAOYSA-N inh1 Chemical compound CC1=CC(C)=CC=C1C1=CSC(NC(=O)C=2C=CC=CC=2)=N1 JPMOKRWIYQGMJL-UHFFFAOYSA-N 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000012660 pharmacological inhibitor Substances 0.000 description 3
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical compound C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102100023013 Basic leucine zipper transcriptional factor ATF-like 3 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100021868 Calnexin Human genes 0.000 description 2
- 108010056891 Calnexin Proteins 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 2
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000006814 Non-Receptor Protein Tyrosine Phosphatases Human genes 0.000 description 2
- 108010086748 Non-Receptor Protein Tyrosine Phosphatases Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- 241000720974 Protium Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100029197 SLAM family member 6 Human genes 0.000 description 2
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 2
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 108020001778 catalytic domains Proteins 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- LTZZZXXIKHHTMO-UHFFFAOYSA-N 4-[[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenyl]methyl]-2H-phthalazin-1-one Chemical compound FC1=C(C=C(CC2=NNC(C3=CC=CC=C23)=O)C=C1)C(=O)N1CCN(CC1)C(C1=CC=C(C=C1)F)=O LTZZZXXIKHHTMO-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100021626 Ankyrin repeat and SOCS box protein 2 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 101000983970 Conus catus Alpha-conotoxin CIB Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101150063370 Gzmb gene Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101150003775 HNF1A gene Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000754299 Homo sapiens Ankyrin repeat and SOCS box protein 2 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000785626 Homo sapiens Zinc finger E-box-binding homeobox 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 101150069380 JAK3 gene Proteins 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 101150078498 MYB gene Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 102000002063 Non-Receptor Type 2 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 102000002001 Non-Receptor Type 6 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010015793 Non-Receptor Type 6 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 1
- 101150061774 PTPN1 gene Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 102000007078 STAT Transcription Factors Human genes 0.000 description 1
- 108010072819 STAT Transcription Factors Proteins 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 101100368917 Schizosaccharomyces pombe (strain 972 / ATCC 24843) taz1 gene Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 101150009943 Tgfb3 gene Proteins 0.000 description 1
- 102000016054 Transcription factor Maf Human genes 0.000 description 1
- 108050004365 Transcription factor Maf Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 101710128895 Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 229960003094 belinostat Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000037966 cold tumor Diseases 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 101150107865 prf1 gene Proteins 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
Definitions
- the subject matter disclosed generally relates to a method for the treatment of cancer, and more specifically to a method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula I, of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof, or combinations thereof, in combination with an immune checkpoint inhibitor.
- CD8 T cells are essential immune system components in mounting antitumoral responses [1]
- TILs tumor infiltrating lymphocytes
- cancer regression is observed after clonal CD8+ cell repopulation in melanoma patients [11], setting the grounds for exploring CD8+ cell based therapies.
- redirection and/or reactivation of immune responses against cancer has been a remarkable source for novel therapies as immune checkpoint blockade [12, 13], Immune checkpoint inhibitors (ICI) anti-PD-1 directed antibodies are extensively used for clinical trial and have been approved by the FDA for almost half of malignancies.
- ICI Immune checkpoint inhibitors
- TCPTP PTPN2
- PTP1 B PTP1 B
- NPTP nonreceptor protein tyrosine phosphatases
- CD8+ cells from mice with conditionally targeted deletions of TCPTP and PTP1 b in mature CD8+ T cells are herein analyzed.
- a method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof:
- R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
- R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
- R 4 ’ and R 5 ’ are each independently selected from the group consisting of:
- aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or C1-3 haloalkyl;
- aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SO X CH 3 , -SO2NH2, Ci. 3 alkyl, Ci. 3 haloalkyl, -OCi. 3 alkyl, or -OC 1.
- R 7 is selected from the group consisting of alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -0C 1-3 alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, alkyl, C1-3 haloalkyl, -CN, -SO X CH 3 , -SO 2 NH 2 , -COOH, and -OC ⁇ alkyl;
- R a and R b are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2; in combination with an immune checkpoint inhibitor.
- a method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula I, or pharmaceutically acceptable salts thereof, and stereoisomers thereof:
- X is selected from CH and N;
- R 2 and 3 ar e independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
- R 4 is selected from the group consisting of (a) H; (b) alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -0C 1 3 alkyl optionally substituted with 1- 3 halogens, -SO X C 1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C ⁇ alkyl or C 1.3 haloalkyl;
- R 5 and R 6 are independently selected from the group consisting of (a) alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC ⁇ alkyl optionally substituted with 1-3 halogens, -SO X C 1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C ⁇ alkyl or C ⁇ haloalkyl;
- a method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a combination of a compound of structural Formula I and of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof:
- X is selected from CH and N;
- R 2 and 3 ar e independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
- R 4 is selected from the group consisting of (a) H; (b) C 1.3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC 1 3 alkyl optionally substituted with 1- 3 halogens, -SO X C 1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C ⁇ alkyl or C 1.3 haloalkyl;
- R 5 and R 6 are independently selected from the group consisting of (a) C 1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC ⁇ alkyl optionally substituted with 1-3 halogens, -SO X C 1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C ⁇ alkyl or C ⁇ haloalkyl;
- R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
- R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
- R 4 ’ and R 5 ’ are each independently selected from the group consisting of:
- aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or C1-3 haloalkyl;
- aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SO X CH 3 , -SO 2 NH 2 , Ci. 3 alkyl, Ci. 3 haloalkyl, -OCi. 3 alkyl, or -OC 1.
- R 7 is selected from the group consisting of C 1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC ⁇ j alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C 1 3 alkyl, Ci- 3 haloalkyl, -CN, -SO X CH 3 , -SO 2 NH 2 , -COOH, and -OC ⁇ alkyl;
- R a and R b are each independently hydrogen or C alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2; in combination with an immune checkpoint inhibitor.
- X’ is selected from CH and N;
- R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
- R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
- R 4 ’ and R 5 ’ are each independently selected from the group consisting of:
- aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or C1-3 haloalkyl;
- R 7 is selected from the group consisting of C 1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC 1 3 alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C 1 3 alkyl, C1-3 haloalkyl, -CN, -SO X CH 3 , -SO 2 NH 2 , -COOH, and -OC ⁇ alkyl;
- R a and R b are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2.
- X is selected from CH and N;
- R 2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
- R 4 is selected from the group consisting of (a) H; (b) C 1.3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC 1 3 alkyl optionally substituted with 1- 3 halogens, -SO X C 1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C ⁇ alkyl or C 1.3 haloalkyl;
- R 5 and R 6 are independently selected from the group consisting of (a) C 1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC ⁇ alkyl optionally substituted with 1-3 halogens, -SO X C 1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C ⁇ alkyl or C ⁇ haloalkyl;
- X is selected from CH and N;
- R 2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
- R 4 is selected from the group consisting of (a) H; (b) C 1.3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC 1-3 alkyl optionally substituted with 1- 3 halogens, -SO X C 1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C ⁇ alkyl or C 1.3 haloalkyl;
- R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
- R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
- R 4 ’ and R 5 ’ are each independently selected from the group consisting of:
- R 7 is selected from the group consisting of C 1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC 1 3 alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C 1 3 alkyl, C1-3 haloalkyl, -CN, -SO X CH 3 , -SO 2 NH 2 , -COCH, and -OC 1.3 alkyl;
- R a and R b are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2.
- the compound of formula II may be of structural Formula Ila, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
- R3’ is halogen
- R 4 and R 5 are each independently selected from the group consisting of:
- aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or C1-3 haloalkyl;
- R 7 is selected from the group consisting of alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -OC 1 3 alkyl, (iii) aryl, and (iv) heteroaryl, wherein wherein the aryl and heteroaryl are optionally substituted with 1-3 halogens, C 1 3 alkyl, C1-3 haloalkyl, -CN, -SO X CH 3 , -SO 2 NH 2 , -COOH, and -OC ⁇ alkyl;
- R a and R b are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2.
- the compound may be selected from the following compounds: or a pharmaceutically acceptable salt thereof.
- the compound of formula (Ila) may be or a pharmaceutically acceptable salt thereof.
- the compound of formula (Ila) may be or a pharmaceutically acceptable salt thereof.
- the compound of Formula I may be of structural Formula la, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof: wherein:
- R 4 is selected from the group consisting of (a) H; and (b) C 1 3 alkyl optionally substituted with 1-5 halogens;
- R 5 and R 6 are independently selected from the group consisting of c 1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC 1 3 alkyl optionally substituted with 1-3 halogens; and
- R 5 and R 6 together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i) halogen, (ii) alkyl optionally substituted with 1-3 halogens, (iii) -OC ⁇ alkyl optionally substituted with 1-3 halogens, (iv) -OH, and (vii) C 1 3 hydroxyalkyl.
- the compound of formula I may be of structural Formula lb, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof: wherein:
- R 4 is selected from the group consisting of (a) H; and (b) alkyl optionally substituted with 1-5 halogens;
- R 5 and R 6 are independently selected from the group consisting of C 1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC ⁇ j alkyl optionally substituted with 1-3 halogens; and
- R 5 and R 6 together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i) halogen, (ii) C 1 3 alkyl optionally substituted with 1-3 halogens, (iii) -OC 1 3 alkyl optionally substituted with 1-3 halogens, (iv) -OH, and (vii) hydroxyalkyl.
- a 1-3 groups independently selected from (i) halogen, (ii) C 1 3 alkyl optionally substituted with 1-3 halogens, (iii) -OC 1 3 alkyl optionally substituted with 1-3 halogens, (iv) -OH, and (vii) hydroxyalkyl.
- the compound may be a compound selected from the following compounds:
- the immune checkpoint inhibitor may be an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or molecular inhibitors of these receptors.
- the anti-PD-1 antibody may be selected from the group consisting of nivolumab antibody, pembrolizumab antibody, pidilizumab antibody, cemiplimab antibody, dostarlimab antibody, JTX-4014 antibody, Spartalizumab antibody, Camrelizumab antibody, Sintilimab antibody, Tislelizumab antibody, Toripalimab antibody, INCMGA00012 antibody, AMP-224 antibody, AMP-514 antibody, RMP1-14 antibody or combinations thereof.
- the anti-PDL-1 antibody may be selected from the group consisting of B7-H1 antibody, BMS-936559 antibody, MPDL3280A (atezolizumab) antibody, MEDI-4736 antibody, MSB0010718C antibody, 10F-9G2 antibody, avelumab antibody, durvalumab antibody, or combinations thereof.
- the anti-CTLA-4 antibody may be selected from the group consisting of ipilimumab or tremelimumab or combinations thereof.
- the administration of the compound of structural Formula I orstructural Formula II may be an intratumoral administration.
- the administration of the compound of structural Formula I or structural Formula II is an oral administration.
- the administration of the immune checkpoint inhibitor may be a systemic administration, and intratumoral administration, or a combination thereof.
- the administration of the compound of structural Formula I orstructural Formula II may be an intratumoral administration and administration of the immune checkpoint inhibitor may be a systemic administration, and intratumoral administration, or a combination thereof, or administration of the compound of structural Formula I may be an intratumoral administration and administration of the immune checkpoint inhibitor may be a systemic administration, an intratumoral administration, or a combination thereof, or administration of the compound of structural Formula I may be an oral administration and administration of the immune checkpoint inhibitor may be a systemic administration, an intratumoral administration, or a combination thereof.
- the compound of structural Formula I or structural Formula II may be administered first, and the immune checkpoint inhibitor is administered second.
- the cancer may be a solid tumor, a prostate cancer, a breast cancer, a brain cancer, a glioma, a lung cancer, a salivary cancer, a stomach cancer, a thymic epithelial cancer, a thyroid cancer, an ovarian cancer, a multiple myeloma, a leukemia, a melanoma, a lymphoma, a gastric cancer, a kidney cancer, a pancreatic cancer, a bladder cancer, a colon cancer and a liver cancer.
- the method or the use of the present invention may further comprise monitoring the activity of the compound of structural Formula I, structural Formula II or both structural Formula I and structural Formula II.
- immunoglobulin refers to a protein constructed from paired heavy and light polypeptide chains; various Ig isotypes exist, including IgA, IgD, IgE, IgG, and IgM.
- VL variable
- CL constant
- VH variable
- Fv antigen binding region
- the present invention further encompasses “monoclonal antibodies” (mAb).
- Monoclonal antibodies are antibodies that are made by identical immune cells which are all clones belonging to a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody).
- FIG. 1A illustrates that CD8 T cells activation and differentiation is increased in naive mice with reduced expression of TCPTP and/or PTP1 B.
- the panels show the CD4 vs CD8 cells from different genotypes. Events shown correspond to single, viable and lineage negative (Lin-) gates.
- Fig. 1 B shows that statistical representation of T cell subtypes from different experiments organized by genotype.
- Fig. 1C shows histogram representation of T cell subtypes from different experiments organized by genotype.
- Fig. 1 D shows the quantification of CD8 low populations in spleen of different genotypes.
- Fig. 1E shows dot plots of CD8 T cell differentiation determined by CD62L and CD44 expression.
- Fig. 1 F shows the statistical representation of CD8 T cell differentiation determined by CD62L and CD44 expression.
- Fig. 1G a histogram representation of differentiation markers EOMES, KLRG1 and CD127.
- Bars represent ⁇ S.E.M.; Two way ANOVA; P values * ⁇ 0.05, ** ⁇ 0.005, *** ⁇ 0.0005, **** ⁇ 0.00005).
- Fig. 1H shows the quantification of differentiation markers EOMES, KLRG1 and CD127.
- Bars represent ⁇ S.E.M.; Two way ANOVA; P values * ⁇ 0.05, ** ⁇ 0.005, *** ⁇ 0.0005, **** ⁇ 0.00005).
- Fig. 2A illustrates the conditional deletion ofTCPTP and PTP1 B in CD8 T cells. Shown is an immunoblot for TCPTP, PTP1 B and Calnexin as loading control from protein homogenates of CD4 and CD8 T cells with different genotypes analyzed.
- Fig. 2B illustrates the thymus size, expressed as weight, from 8-12-week-old male mice carrying the different genotypes analyzed.
- Fig. 2C illustrates the hematoxylin and eosin staining of thymus sections from 10-week- old CRE controls orTCPTP/PTP1 B (dKO) CD8 specific “knockouts”.
- Fig. 2D shows spleen and inguinal lymph node size (by weight) and cellularity from the different genotypes analyzed.
- Fig. 2E shows the total number of CD4 and CD8 T cells from spleen and inguinal lymph nodes shown in Fig. 1 B.
- Fig. 3A illustrates that mouse CD8 T cells deficient in TCPTP and/or PTP1 B are more cytotoxic and reach terminal differentiation.
- OT-1 CD8 T cells with different Ptpnl and/or Ptpn2 deletions were activated/expanded with aCD3/aCD28 antibodies and IL-2.
- Day 5 cells were tested for specific cytotoxicity against the OVA expressing E.G7 thymoma cells.
- Fig. 3B shows statistical representation of several experiments from Fig. 3A.
- Fig. 3C shows ELISA quantification of IFN-y in supernatants from Fig. 3A.
- Fig. 3D shows flow cytometry plots of CD8 T cell differentiation determined by CD62L and CD44 expression.
- Fig. 3E shows bar representation of percentages of CD8 T cell differentiation determined by CD62L and CD44 expression.
- Fig. 4 illustrates the in vitro cytotoxicity against specific target cells of CD8 T cells with genetic deficiency of TCPTP and/or PTP1 B. Statistical representation of day 5 CTLs from all the different genotypes tested for specific cytotoxicity against the OVA expressing E.G7 thymoma cells.
- Fig. 5A Illustrates that pharmacological inhibition of TCPTP and PTP1 B results in enhanced cytotoxicity and effector differentiation.
- CD8 T cells from OT-1 mice were activated/expanded by aCD3/aCD28 antibodies and IL-2 in the presence of different concentrations of TCPTP/PTP1 B inhibitor (I n h 1 ) for 5 days.
- Specific cytotoxicity against OVA expressing E.G7 thymoma cells was measure.
- Fig. 5C shows the ELISA quantification of IFN-y in supernatants from Fig. 5A.
- Fig. 5D shows flow cytometry plots of CD8 T cell differentiation determined by CD62L and CD44 expression.
- Fig. 5E shows bar representation of percentages of CD8 T cell differentiation determined by CD62L and CD44 expression.
- Fig. 5F shows the cytotoxicity of CD8 T cells from animals with different TCPTP and PTP1B genotypes, additionally treated with Ihn1.
- Fig. 5G shows ELISA quantification of IFN-y in supernatants from Fig. 5F.
- In each panel bars represent ⁇ S.E.M.; Two-way ANOVA; P values * ⁇ 0.05, ** ⁇ 0.005, *** ⁇ 0.0005, **** ⁇ 0.00005).
- Fig. 6A illustrates that pharmacological inhibition of TCPTP and PTP1 B in human T cells results in enhanced proinflammatory cytokine secretion and Tern differentiation.
- Purified T cells from human donors were activated by aCD3/aCD28 and analyzed at day 7 for IFN-y and TNF-a by flow cytometry. Shown are plots of cells gated in CD4 and CD8 populations distributed by IFN-y and TNF-a expression.
- Fig. 6B shows bar graphs showing statistical representation of 2 biological replicates for CD4 and CD8 populations distributed by IFN-y expression.
- Fig. 6C shows bar graphs showing statistical representation of 2 biological replicates for CD4 and CD8 populations distributed by TNF-a expression.
- Fig. 6D shows bar graphs presenting the percentage of Effector Memory T cell (Tern) and Central memory T cell (Tern) based on the selection of CD45 RO high and CD62L high ratio with orwithout inh 1 in CD4 and CD8 T cells.
- Fig. 7A illustrates the pharmacological inhibition of TCPTP and PTP1B in human T cells. Normalized percentual representation of experiments in Fig. 5 showing IFN-y.
- Fig. 7B illustrates the pharmacological inhibition of TCPTP and PTP1B in human T cells. Normalized percentual representation of experiments in Fig. 5 showing TNF-a.
- Fig. 7C shows the percentual contribution of CD4 and CD8 T cells of in vitro human T cell cultures at day 7.
- Fig. 8A illustrates the bulk mRNA analysis of CD8 T cells deficient in TCPTP and/or PTP1B or treated with Inh1. Heatmap of genes differentially expressed in the genotypes analyzed is shown. Organized as opposing expression between TCKO/1BHet CD8 T cells and CRE controls. Overexpressed genes showed as gradual red shift, under expressed genes as gradual blue shift.
- Fig. 8B illustrates a volcano plot illustrating the significant differentially expressed genes between TCKO and TCKO/1B Het CD8 cells (FDR 5%).
- Fig. 8C illustrates a dot plot corresponding to selected list of genes with relevancy to CD8 T cells, activation/differentiation. Overexpressed genes showed as gradual red shift, under expressed genes as gradual blue shift.
- Fig. 9A illustrates bulk mRNA analysis of CD8 T cells deficient in TCPTP and/or PTP1 B or treated with Inh 1. Volcano plots representing the significant differentially expressed genes between day 5 CTLs from CRE controls and the different genotypes analyzed.
- Fig. 9B illustrates the significant differentially expressed genes between day 5 CTLs form C57BL/6 mice, treated or not with 5 pM I nh 1 .
- Fig. 9C illustrates the differential expression of the different members of the NR4A transcription factor family from samples in A) and B).
- Fig. 9D illustrates the secretion of IL-10 from CTLs carrying different TCPTP and PTP1B mutations, treated or not with 5 pM Inh1. Determined by ELISA from supernatants form Fig. 1 F.
- Fig. 10A illustrates the global changes of STAT expression and phosphorylation in CD8T cells with reduced or absent TCPTP/PTP1B activity. Shown is an immunoblot of day 5 CTLs stimulated with rmIFN-p for the indicated times.
- Fig. 10B illustrates the global changes of STAT expression and phosphorylation in CD8T cells with reduced or absent TCPTP/PTP1B activity. Shown is an immunoblot of day 5 CTLs stimulated with rmIFN-p for the indicated times.
- Fig. 10C illustrates the global changes of STAT expression and phosphorylation in CD8T cells with reduced or absent TCPTP/PTP1 B activity. Shown is a representation of densitometric analysis. (Representative of at least 3 experiments).
- Fig. 11A illustrates the increased expression of transcription factors in CD8T cells with reduced or absent TCPTP/PTP1B activity. Shown is the specific cytotoxicity against OVA expressing E.G7 thymoma cells from 5-day TCKO/1BHet CTLs transfected with no target or BATF3 siRNAs.
- Fig. 11 B illustrates an immunoblot with specific BATF3 and calnexin antibodies to demonstrated specific deletion.
- Fig. 11C illustrates an immunoblot analysis of cell homogenates from the different CTL genotypes analyzed, probed with antibodies for several transcription factors.
- Fig. 12A illustrates that TCPTP / PTP1 B pharmacological inhibitors have similar affinity for both enzymesand that intratumoral injection of Inh1 results in tumor regression. Shown is a timeline of tumor volume after subcutaneous injection of 3 x 10 5 EG.7 OVA expressing thymoma cells in C57BL/6 mice. Mice were subjected to treatment by intratumoral injection of equivalent to 50 pM I nh1 every 2 days, or PBS as control. (Shown one of two experiments).
- Fig. 12B illustrates the in vitro phosphatase activity of TCPTP and PTP1B catalytic domains in presence of increasing concentrations of In h 1 and Inh2.
- Table at right shows average IC50 from 3 experiments.
- Fig. 12C illustrates the specific cytotoxicity against OVA expressing E.G7 thymoma cells from 5-day C57BL/6 CTLs treated with Inh1 or Inh2 at the concentrations specified, (one of three experiments shown).
- a-PD1 anti-PD-1 mAb
- Inh2 TCPTP / PTP1 B inhibitor
- Fig. 13B illustrates the statistical comparison of all groups for experiment A) (Tukey’s multiple comparison test with 95% confidence intervals).
- Fig. 13C illustrates survival curve determined by humane endpoint intervention. (Data from one of two independent experiments).
- FIG. 14A illustrates an immunoblotting analysis of Statl phosphorylation in PBMC of C57BL/6 mice after 2 hours of intraperitoneal injection of Inh2.
- Fig 14B illustrates an immunoblotting analysis of Stat3 phosphorylation in PBMC of C57BL/6 mice after 2 hours of intraperitoneal injection of Inh2.
- Compounds of Formula I and/or Formula II are inhibitors of both PTPN1 (PTP1 B) and PTPN2 (TCPTP).
- T lymphocytes deficient in TCPTP, or deficient in TCPTP and additionally hemideficiency of PTP1B display enhanced pro-cytotoxic abilities.
- Small molecule inhibitors targeting specifically both the PTP1 B and TCPTP enzymes showed a remarkable enhancement of treated CD8 T cells in mouse and human cells, providing therapeutic use in solid tumors.
- the present invention relates to a method for the treatment of cancer by administering a therapeutically effective amount of a compound of structural Formula I, of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof, or combinations thereof, in combination with an immune checkpoint inhibitor, to a subject in need thereof.
- the present invention relates to a method for the treatment of PTP1 B and TCPTP dependent diseases, such as for example cancer, by administering a therapeutically effective amount of a compound of structural Formula I, of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof, or combinations thereof, in combination with an immune checkpoint inhibitor, to a subject in need thereof.
- Types of cancer that may be treated by compounds of the present invention include, but are not limited to, prostate cancer, breast cancer, brain cancer, glioma, lung cancer, salivary cancer, stomach cancer, thymic epithelial cancer, thyroid cancer, ovarian cancer, multiple myeloma, leukemia, melanoma, lymphoma, gastric cancer, kidney cancer, pancreatic cancer, bladder cancer, colon cancer and liver cancer.
- Ac is acetyl [CH3C(O)-], AC2O is acetic anhydride; ACN is acetontrile; APC is antigen- presenting cell; Aik is alkyl; Ar is aryl; 9-BBN is 9-borabicyclo[3.3.1]nonane; Bn is benzyl; BOC is tert Butyloxycarbonyl; br is broad; CH2CI2 is dichloromethane; d is doublet; DBU is 1 ,8-
- RECTIFIED SHEET (RULE 91 ) diazabicyclo[5.4.0]undec-7-ene; DC is dendritic cell; DEAD is diethyl azodicarboxylate; DIAD is diisopropylazodicarboxylate; DIBAL is diisobutylaluminum hydride; DIPEA is N,N- diisopropylethylamine; DMF is N,N-dimethylformamide; DMSO is dimethyl sulfoxide; EDAC (or EDC) is 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide HCI; ESI is electrospray ionization; EtsN is triethylamine; Et is ethyl; EtOAc is ethyl acetate; EtOH is ethanol; 3-F-Ph is 3-fluorophenyl; h is hours; HATU is O-(7-azabenzotria
- Alkyl as well as other groups having the prefix “alk”, such as alkoxy and alkanoyl, means carbon chains which may be linear or branched, and combinations thereof, unless the carbon chain is defined otherwise.
- alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like.
- the term alkyl also includes cycloalkyl groups, and combinations of linear or branched alkyl chains combined with cycloalkyl structures. When no number of carbon atoms is specified, C1-6 is intended.
- Cycloalkyl is a subset of alkyl and means a saturated carbocyclic ring having a specified number of carbon atoms.
- Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.
- a cycloalkyl group generally is monocyclic unless stated otherwise. Cycloalkyl groups are saturated unless otherwise defined.
- alkoxy refers to straight or branched chain alkoxides of the number of carbon atoms specified (e.g., C1-6 alkoxy), or any number within this range [i.e., methoxy (MeO-), ethoxy, isopropoxy, etc.].
- alkylthio refers to straight or branched chain alkylsulfides of the number of carbon atoms specified (e.g., C1-6 alkylthio), or any number within this range [i.e., methylthio (MeS-), ethylthio, isopropylthio, etc.].
- alkylamino refers to straight or branched alkylamines of the number of carbon atoms specified (e.g., C1-6 alkylamino), or any number within this range [i.e., methylamino, ethylamino, isopropylamino, t-butylamino, etc.].
- alkylsulfonyl refers to straight or branched chain alkylsulfones of the number of carbon atoms specified (e.g., C1-6 alkylsulfonyl), or any number within this range [i.e., methylsulfonyl (MeSO2 _ ), ethylsulfonyl, isopropylsulfonyl, etc.].
- alkylsulfinyl refers to straight or branched chain alkylsulfoxides of the number of carbon atoms specified (e.g., C-i-6 alkylsulfinyl), or any number within this range [i.e., methylsulfinyl (MeSO-), ethylsulfinyl, isopropylsulfinyl, etc.].
- alkyloxycarbonyl refers to straight or branched chain esters of a carboxylic acid derivative of the present invention of the number of carbon atoms specified (e.g., C-i-e alkyloxycarbonyl), or any number within this range [i.e., methyloxycarbonyl (MeOCO ), ethyloxycarbonyl, or butyloxycarbonyl].
- Aryl means a mono- or polycyclic aromatic ring system containing carbon ring atoms.
- the preferred aryls are monocyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls. The most preferred aryl is phenyl.
- Heterocyclyl refer to saturated or unsaturated non-aromatic rings or ring systems containing at least one heteroatom selected from O, S and N, further including the oxidized forms of sulfur, namely SO and SO2.
- heterocycles include tetra hydrofuran (THF), dihydrofuran,
- Heteroaryl means an aromatic or partially aromatic heterocycle that contains at least one ring heteroatom selected from O, S and N. Heteroaryls thus include heteroaryls fused to other kinds of rings, such as aryls, cycloalkyls and heterocycles that are not aromatic. Examples of heteroaryl
- RECTIFIED SHEET (RULE 91 ) groups include: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl (in particular, 1 ,3,4-oxadiazol-2-yl and 1 ,2,4-oxadiazol-3-yl), thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, triazinyl, thienyl, pyrimidyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzofuranyl, indolinyl, pyridazinyl, indazolyl, isoindolyl, dihydrobenzothienyl, indolizinyl, cinnolinyl, phthalazinyl, qui
- Halogen refers to fluorine, chlorine, bromine and iodine. Chlorine and fluorine are generally preferred. Fluorine is most preferred when the halogens are substituted on an alkyl or alkoxy group (e.g. CF3O and CF3CH2O).
- composition « as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
- Such term in relation to pharmaceutical composition is intended to encompass a product comprising the active ingredient(s) and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
- the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable or “acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- T cell(s) » « T lymphocyte(s) » « T cell product(s) » as used herein are intended to encompass isolated tumor-infiltrating lymphocyte (TIL), T cell receptor (TCR) engineered cell, and/or chimeric antigen receptor (CAR) engineered cell isolated by the method of the present invention. It also includes different memory T cell populations such as Stem central memory TSCM cells, Central memory TCM cells and Effector memory TEM cells, that are beneficial to mount and maintain surveillance and Immune response.
- TIL tumor-infiltrating lymphocyte
- TCR T cell receptor
- CAR chimeric antigen receptor
- PTPN1 tyrosine-protein phosphatase non-receptor type 1 , also known as protein-tyrosine phosphatase 1B (PTP1 B), and is an enzyme that is the founding member of the protein tyrosine phosphatase (PTP) family. In humans it is encoded by the PTPN1 gene.
- PTP1 B is a negative regulator of the insulin signaling pathway and is
- RECTIFIED SHEET (RULE 91 ) considered a promising potential therapeutic target, in particular for treatment of type 2 diabetes. It has also been implicated in the development of breast cancer and has been explored as a potential therapeutic target in that avenue as well.
- PTPN2 as used herein is intended to mean the tyrosine-protein phosphatase non-receptor type 2, also known as T-cell protein-tyrosine phosphatase (TCPTP, TC- PTP), and in humans is encoded by the PTPN2 gene.
- TCP T-cell protein-tyrosine phosphatase
- the present invention uses compounds of structural Formula I, or of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof, or combinations thereof.
- the compounds structural Formula I are the following: wherein:
- X is selected from CH and N;
- R 2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
- R 4 is selected from the group consisting of (a) H; (b) C 1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC 1 3 alkyl optionally substituted with 1- 3 halogens, -SO X C 1 3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C 1 3 alkyl or C 1 3 ha lo a I ky I;
- R 5 and R 6 are independently selected from the group consisting of (a) C 1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC 1 3 alkyl optionally substituted with 1-3 halogens, -SO X C 1-3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C 1 3 alkyl or C 1 3 haloalkyl;
- the compounds of structural formula I include compounds of structural Formula la, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof: wherein:
- R 4 is selected from the group consisting of (a) H; and (b) C 1 3 alkyl optionally substituted with 1 -5 halogens;
- R 5 and R 6 are independently selected from the group consisting of C 1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC 1 3 alkyl optionally substituted with 1-3 halogens; and
- R 5 and R 6 together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i)
- RECTIFIED SHEET (RULE 91 ) halogen, (ii) C 1 3 alkyl optionally substituted with 1 -3 halogens, (iii) -OC 1 3 alkyl optionally substituted with 1 -3 halogens, (iv) -OH, and (vii) C 1 3 hydroxyalkyl.
- the compounds of structural formula I include compounds of structural Formula lb, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof: wherein:
- R 4 is selected from the group consisting of (a) H; and (b) C 1 3 alkyl optionally substituted with 1 -5 halogens;
- R 5 and R 6 are independently selected from the group consisting of C 1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC 1 3 alkyl optionally substituted with 1-3 halogens; and
- R 5 and R 6 together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i) halogen, (ii) C 1 3 alkyl optionally substituted with 1 -3 halogens, (iii) -OC 1 3 alkyl optionally substituted with 1 -3 halogens, (iv) -OH, and (vii) C 1 3 hydroxyalkyl.
- the compounds of structural Formula I may be compounds selected from the following compounds:
- R1’ is selected from the group consisting of (a) Ci -3a Iky I optionally substituted with 1- 3 halogens and optionally with one group selected from -OH, -OC-
- -3alkyl optionally substituted with 1-3 halogens, (h) -(CH3)C NOC-
- .salkyl optionally substituted with 1-3 halogens (i) -C( O)OC-
- .salkyl optionally substituted with 1-3 halogens, (j) -C( O)N
- R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
- R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
- R 4 ’ and R 5 ’ are each independently selected from the group consisting of:
- R6’ js selected from the group consisting of H, C-
- -3alkyl optionally substituted with 1 - 3 halogens, Phenyl, and -CH2-Phenyl, wherein Phenyl in both occurrences is optionally substituted with 1 -3 substituents independently selected from (i) halogen, (ii) -C( O)OC-
- R 7 is selected from the group consisting of C 1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC 1 3 alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1 -3 halogens, C 1 3 alkyl, C1-3 haloalkyl, -CN, -SO X CH 3 , -SO 2 NH 2 , -COOH, and -OC ⁇ alkyl;
- R a and R b are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2;
- the compound of formula II may be of structural Formula Ila, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
- R3’ is halogen
- R 4 and R 5 are each independently selected from the group consisting of:
- aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C-
- RECTIFIED SHEET (RULE 91 ) halogens, (iii) -COOH, (iv) C 1 3 alkyl optionally substituted with 1 -3 halogens, and (v) -OC 1 3 alkyl optionally substituted with 1-3 halogens;
- R 7 is selected from the group consisting of C 1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -OC 1 3 alkyl, (iii) aryl, and (iv) heteroaryl, wherein wherein the aryl and heteroaryl are optionally substituted with 1 -3 halogens, C 1 3 alkyl, C1-3 haloalkyl, -CN, -SO X CH 3 , -SO 2 NH 2 , -COOH, and -OC ⁇ alkyl;
- R a and R b are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1 -5 fluorines; and x is 0, 1 , or 2.
- the compound of structural Formula II may be selected from the following compounds:
- Compounds of structural Formula I, structural Formula la and/or structural Formula lb and/or structural Formula II and/or structural Formula Ila may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of structural Formula I, structural Formula la and/or structural Formula lb.
- Compounds of structural Formula I, structural Formula la, structural Formula lb and/or structural Formula II and/or structural Formula Ila may be separated into their individual diastereoisomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof, or via chiral chromatography using an optically active stationary phase.
- Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
- any stereoisomer of a compound of the general structural Formula I, structural Formula la, structural Formula lb and/or structural Formula II and/or structural Formula Ila may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known absolute configuration.
- racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated.
- the separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography.
- the coupling reaction is often the formation of salts using an enantiomerically pure acid or base.
- the diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
- the racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
- Some of the compounds described herein may exist as tautomers, which have different points of attachment of hydrogen accompanied by one or more double bond shifts.
- a ketone and its enol form are keto-enol tautomers.
- the individual tautomers as well as mixtures thereof are encompassed with compounds of the present invention.
- the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may 42
- RECTIFIED SHEET (RULE 91 ) be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
- the present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I, Formula la, Formula lb and/or structural Formula II and/or structural Formula Ila.
- different isotopic forms of hydrogen (H) include protium ( 1 H) and deuterium ( 2 H).
- Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
- Isotopically-enriched compounds within generic Formula I, Formula la, Formula lb, Formula II and/or Formula Ila can be prepared without undue experimentation by conventional techniqueswell known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
- subject is a human patient or other animal such as another mammal with functional mast cells, basophils, neutrophils, eosinophils, monocytes, macrophages, dendritic cells, and Langerhans cells.
- references to the compounds of structural Formula I, Formula la, Formula lb, Formula II and/or Formula Ila are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they 43
- RECTIFIED SHEET (RULE 91 ) are used as precursors to the free compounds or their pharmaceutically acceptable salts or in other synthetic manipulations.
- pharmaceutically acceptable salt refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed within the term “pharmaceutically acceptable salt” referto non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
- Representative salts of basic compounds of the present invention include, but are not limited to, the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate),
- suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
- basic ion-exchange resins such as arginine, betaine, caffeine, choline, N,N
- esters of carboxylic acid derivatives such as methyl, ethyl, or pivaloyloxymethyl
- acyl derivatives of alcohols such as acetyl, pivaloyl, benzoyl, and aminoacyl
- esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations.
- Solvates, in particular hydrates, of the compounds of structural Formula I, Formula la, Formula lb, Formula II and/or Formula Ila are included in the present invention as well.
- the pharmaceutical compositions may be in the form of a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1 ,3- butane diol.
- a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1 ,3- butane diol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- immune checkpoints The role of immune checkpoints is to prevent an immune response from being so strong that it destroys healthy cells in the body.
- Immune checkpoints engage when proteins on the surface of T cells recognize and bind to partner proteins on other cells, such as some tumor cells. These proteins are called immune checkpoint proteins. When the checkpoint and partner proteins bind together, they send an “off’ signal to the T cells. This can prevent the immune system from destroying the cancer.
- Immunotherapy drugs called immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off’ signal from being sent, allowing the T cells to kill cancer cells.
- One such drug acts against a checkpoint protein called CTLA-4.
- Other immune checkpoint inhibitors act against a checkpoint protein called Programmed cell death protein 1 , also known as PD-1 or its partner protein Programmed death-ligand 1 (PD-L1 ). Some tumors turn down the T cell response by producing lots of PD-L1.
- checkpoint inhibitors are anti-PD1 and anti-CTLA4, yet in the interaction of dendritic cells with tumors cells, effector T-cells, and other immune cells, a number of protein interactions favoring or inhibiting the recognition and killing of tumor cells has been identified. For example, a dozen of those interactions have been reported to affect DC and tumors cells (K. Palucka and J. Banchereau, Nature Reviews Cancer 12:265-277). Hence the technology described herein may be conjugated to many of those additional immunotherapy technologies currently in development.
- the immune checkpoint inhibitor may therefore be an anti- PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or molecular inhibitors of these receptors.
- the anti-PD-1 antibody may be selected from the group consisting of nivolumab antibody, pembrolizumab antibody, pidilizumab antibody, cemiplimab antibody, dostarlimab antibody, JTX-4014 antibody, Spartalizumab antibody, Camrelizumab antibody, Sintilimab antibody, 45
- RECTIFIED SHEET (RULE 91 ) Tislelizumab antibody, Toripalimab antibody, INCMGA00012 antibody, AMP-224 antibody, AMP-514 antibody, RMP1-14 antibody or combinations thereof.
- the anti-PDL-1 antibody may be selected from the group consisting of B7-H1 antibody, BMS-936559 antibody, MPDL3280A (atezolizumab) antibody, MEDI-4736 antibody, MSB0010718C antibody, 10F-9G2 antibody, avelumab antibody, durvalumab antibody, or combinations thereof.
- the anti-CTLA-4 antibody may be selected from the group consisting of ipilimumab or tremelimumab or combinations thereof.
- the compounds specifically exemplified herein exhibit good efficacy in inhibiting the PTPN1/PTP1 B and PTPN2/TCPTP enzymes, as shown by their in vitro assays.
- the compounds generally have an IC50 value of less than 10 pM in the enzyme assay described in the Assays section, and preferably have an IC50 value of less than 1 pM.
- One aspect of the invention provides a method for the treatment and control of cancer, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula I, Formula la, Formula lb, Formula II and/or compounds of Formula Ila, in combination with an immune checkpoint inhibitor.
- a therapeutically effective amount of a compound of Formula I, Formula la, Formula lb, Formula II and/or compounds of Formula Ila in combination with an immune checkpoint inhibitor.
- the compound of Formula I, Formula la, Formula lb, Formula II and/or compounds of Formula Ila and the immune checkpoint inhibitor provide an unexpectedly enhanced treatment that may not be obtained from the treatment with either component alone.
- mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent, such as a mouse, can be treated.
- the method can also be practiced in other species, such as avian species (e.g., chickens).
- Compounds of Formula I, Formula la, Formula lb, Formula II and Formula Ila when being used for treatment purposes may be packaged for use as a crystalline solid, an amorphous solid or a lyophilized powder. Suitable quantities range from about 0.1 mg to 1 g. Ideally, the compound is packaged in a container to which a suitable solvent can be added to achieve the desired concentration of solution. Alternatively, the compound may be packaged as an aqueous solution at a fixed concentration, or as a solution in a water-soluble organic solvent at a fixed concentration. Suitable 46
- organic solvents may include DMSO, methanol, ethanol or acetonitrile, or mixtures of these solvents with water. Suitable concentrations are about 0.1 mM to about 25 mM.
- kits encompassing the compounds of Formula I, Formula la, Formula lb, formula II and/or Formula Ila, and instructions on how to use said compounds.
- the kit may also include appropriate immune checkpoint inhibitor.
- the kit will allow a patient to be conveniently treated. This treatment can be optimized to work best with current clinical therapeutic standards.
- the compound of Formula I, Formula la, Formula lb, Formula II and/or Formula Ila may be administered to a patient in need of immunotherapy in one or more injections.
- the frequency of injection and the intervals between injections of the compound and/or immune checkpoint inhibitor will be adjusted to maximize the therapeutic response. For example, injections may occur once, twice, or more times daily, once, twice, or more times weekly, biweekly, monthly or bimonthly or at any other intervals deemed most suitable to the therapeutic benefit of the patient.
- the compound of Formula I, Formula la, Formula lb, Formula II and/or Formula Ila may be administered prior to administration of the immune checkpoint inhibitor.
- the administration of the compound of Formula I, Formula la, Formula lb, Formula II and/or Formula Ila may be an intratumoral administration.
- the administration of the compound of structural Formula I, Formula la, Formula lb, Formula II and/or Formula Ila may be an oral administration.
- the administration of the immune checkpoint inhibitor may be a systemic administration, and intratumoral administration, or a combination thereof.
- the administration of said compound of structural Formula I, Formula la, Formula lb, Formula II and/or Formula Ila may be an intratumoral administration and the administration of the immune checkpoint inhibitor may be a systemic administration, an intratumoral administration, or a combination thereof, or the administration of the compound of structural Formula I may be an intratumoral administration and administration of the immune checkpoint inhibitor may be a systemic administration, an intratumoral administration, or a combination thereof, or administration of the compound of structural Formula I may be an oral administration and administration of the immune checkpoint inhibitor may be a systemic administration, an intratumoral administration, ora combination thereof.
- a patient in need of immunotherapy may be treated with the compound of Formula I, Formula la, Formula lb, Formula II and/or Formula Ila and the immune checkpoint inhibitor, contemporaneously with other treatments known to the medical practitioner.
- the use of such multiple 47 may be used with the compound of Formula I, Formula la, Formula lb, Formula II and/or Formula Ila and the immune checkpoint inhibitor, contemporaneously with other treatments known to the medical practitioner.
- RECTIFIED SHEET treatments may be particularly advantageous to the patient. Such treatments may include, but are not limited to, surgical resection, radiation, chemotherapy, targeted therapy and other types of immunotherapy.
- Chemotherapy agents that may be used include: a) cytotoxic agents such as taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 -dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof; b) antimetabolites such as methotrexate, 6-mercaptopurine, 6-thioguanine
- the methods or uses of the present invention may further comprise monitoring the activity of the compound of structural Formula I, structural Formula II or both structural Formula I and structural Formula II during their respective uses.
- targeted cells such as PBMCs can be collected from blood drawn from a patient treated with the compounds of the present invention, and the phosphorylation states of downstream targets of TCPTP
- RECTIFIED SHEET (RULE 91 ) (PTPN2) and PTP1B (PTPN1 ) may be monitored.
- the monitoring may take place by immunoblotting, but could also take place through other means of measuring the phosphorylation states of these downstream targets.
- monitoring could be performed by measuring the fluorescence from a fluorescently labelled antibody specific to any one of the PTPN1/PTPN2 downstream targets, by Fluorescent activated Cell Sorting, mass spectrometry and others.
- mice where allelic inactivation of either one or both of these genes was specifically induced in mature CD8+ T cells.
- heterozygous mice carrying “floxed” alleles of both genes TCPTP [30] and PTP1B [31] were bred with a mouse line where the CRE recombinase expression is driven by the CD8 enhancer 8I (E8i-CRE) [32]
- Mice were bred to produce littermates with either WT (wt/wt), heterozygous (wt/fl) or homozygous (fl/fl) versions of either single TCPTP or PTP1 B, or both genes.
- mice heterozygous E8i-CRE (wt/cre+) expression was maintained to achieve deletion.
- mice heterozygous for E8i-CRE (wt/cre+) carrying wt alleles for TCPTP and PTP1 B were used as controls, here after named CRE.
- Mice were born at mendelian rates, and no apparent differences were detected between the various genotypes until 6-8 weeks of age.
- mice with dKO CD8 T cells showed an increase in the CD4/CD8 T cell ratio in lymph nodes.
- the absolute number of T cells was not significantly affected (Figs. 1A, 1 B and 2E). This finding, together with the size increase of lymph nodes suggested a change in the migratory cues of lymph nodes. No other significant differences in the distribution of T cells in lymph nodes or spleen was noted.
- CD8 T cells in lymph nodes showed a marked increase of effector/effector memory like CD8 T cells in the TCKO/1 BHet mice (ptpnl wt/fl; Ptpn2 fl/fl; wt/cre+) and dKO mice.
- This subset of CD8+ T cells characterized by reduced expression of CD62L and intermediate expression of CD44, correlated with the presence CD8low cells (Fig. 1 D). To determine if this correlation was indeed obtained from a distinct differentiation state of the CD8low subpopulation the expression of known CD8 differentiation markers in these cells was compared with the CD8high subpopulation.
- OT-1 mice express a T cell receptor (TCR) with affinity for an epitope of chicken ovalbumin (OVA 257- 64) recognized in context of the MHC Class I.
- OVA specific activated cytotoxic lymphocytes (CTL) were generated in vitro from purified splenic CD8+ T cells of mice with different genotypes. Day 5 CTL cells were then challenged with the OVA expressing thymoma cell line E.G7 in 5-hour in vitro cytotoxicity assays (Figs. 3A, 3B and 4A).
- Effector CD8 T cells also contribute to the immune response by the secretion of cytokines as IFN-y, consequently the presence of this cytokine in the supernatant of target cell stimulated CTLs by ELISA was measured.
- An increase of the secretion of IFN-y was detected in TCPTP and PTP1 B single deficient cells at low effector to target ratios which was more stepped in the PTPN2 KO cells (Fig. 3C).
- a significant reduction of IFN-y concentration was observed in the supernatants from dKO CTLs, more evident in low effector to target ratios while no significant changes were seen in the TCKO/1 BHet, which were conversely the most efficient at tumor lysis (Fig. 3C).
- OT-1 CTLs were generated in vitro in presence of various concentrations (2, 5 and 10 pM) of Inh, 1 and they were tested at day 5 in cytotoxic assays against E.G7 targets (Figs. 5A and 5B).
- cytokine secretion seems to be also affected by the reduced activity of TC-PTP and PTP1 B IFN-y secretion was quantified in the supernatant of these experiments by ELISA (Fig.
- IFN-y secretion was higher in the lower effector to target ratios, suggesting that low levels of stimulation favor proinflammatory cytokine secretion.
- presence of the inhibitor at low concentration (2 pM) correlated with a more significant increase in the secretion of IFN-y, resembling observations in the single TC-PTP or PTP1 B deficient cells. Additionally, increasing the concentration of the inhibitor led to an opposite effect on IFN-y secretion, similarly to that observed in the TCKO/1 BHet or the dKO derived CTLs.
- CD8 T cell of the different the genotypes used previously were treated with 5 pM Inh1 during in vitro CTL differentiation and tested for specific cytotoxicity against E.G7 cells (Fig. 3F).
- CRE controls increased their capacity to lyse E.G7 target cells about 2-fold.
- cytotoxicity followed a pattern without significant differences to 52
- PTP1 B is targeted intracellularly by the inhibitor and the pharmacological inhibition with 5 pM Inh1 has a comparable effect to the observations in the PTP1B hemizygous cells.
- the inhibitor did not have an effect on eitherTCKO/1 BHet ordKO CTLs cytotoxic capacities, suggesting that in both of these genotypes, cells are brought to their maximum effector capabilities (Fig. 5F).
- IFN-y was measured in the cell supernatant of these experiments.
- cells stimulated at 5 to 1 effector to target ratio in either genetically deficient in TCPTP or those treated with the inhibitor had the highest IFN-y secretion (Fig. 5G).
- reduced activity of TCPTP and PTP1 B led to a decrease in the secretion of IFN-y.
- T cells were enriched from healthy donors PBMCs and stimulated in vitro with anti-CD3 and anti CD28 for 7 days in the presence of increasing amounts of Inh 1.
- the cells were harvested and analyzed by surface and intracellular flow cytometry forthe proinflammatory cytokines IFN-y and TNF- a, and forthe differentiation markers CD45RO and CD62L defining effector and memory populations.
- In vitro treatment of human T cells with Inh 1 led to an increase in the production and accumulation of both IFN-y and TNF-a in both CD4 and CD8 T cells (Figs. 6A, 6B, 7A and 7B).
- Figs. 8 and 9 To eliminate bias given by the changes in peripheral CD8 differentiation observed in vivo, we generated CTLs were generated from purified naive splenic CD8 T cells. The most significantly differentially expressed genes were observed when comparing 1 BKO and dKO samples to CRE controls (Fig. 9A).
- This list of differentially expressed genes shows a transcriptome that leans towards an effector T cell phenotype, characterized by positively regulated effector genes such as Prf1 , and Gzmb, potentially as consequence of the down regulation of the transcription factors Tcf7 and EOMES [38], and down regulation of the naTve/memory marker Sell (CD62L). It was also noticed that the triggering of counter-modulatory mechanisms, as the inhibitory receptor klrkl, the Jak/STAT regulator ASB2 and the cytokines IL-10, Tgfb3 and cytokine receptor for IL-13, IL-13ra1 , were upregulated, potentially by the presence of the transcription factor Maf, which was also found increased.
- TCPTP deficiency corresponds to an increase in effector molecule expression (e.g., granzymes and perforin), reduction of migratory receptors to secondary immune organs (e.g., CD62L and CCR7), mild
- RECTIFIED SHEET (RULE 91 ) expression of inhibitory receptors (e.g., PD1 , Tigit and Tim-3), and increased expression of chemokines CCL3, 4 and 5.
- inhibitory receptors e.g., PD1 , Tigit and Tim-3
- chemokines CCL3, 4 and 5 chemokines
- BKO cells transcriptome resembled that of memory T cells, characterized by the upregulation of the IL-7 receptor CD127, CD62L, CXCR5 and CD28, and upregulation of the transcription factor Tcf1. These cells also showed characteristics of exhausted T cells like high expression of the inhibitory receptors Tigit, SLAMF6, CD38 and CTLA4. Similarly, although the transcriptome of dKO cells correlated to that of single TCPTP KO cells, these dKO cells also expressed higher levels of receptors associated with exhaustion, as Tim-3, Tigit, Lag3, Entpdl and PD-1.
- IL-10 is one of the highly upregulated mRNA species in the TCKO, TCKO/1 BHet, dKO and the T cells treated with the inh1. T radition ally considered as a regulatory cytokine, IL-10 has been more recently associated to improved antitumoral responses and prevention of CD8 T cell exhaustion. The presence of IL-10 in the supernatants of in vitro cytotoxicity assays was tested by ELISA (Fig. 9D).
- IL-10 secretion in these conditions followed an almost identical pattern to the findings in cytotoxicity discussed above.
- PTP1B single deficient T cells were no different than CRE controls.
- TCKO, TCKO/1 BHet and dKO cells showed a gradual increment of IL-10 secretion in their corresponding supernatants.
- additional treatment with 5 M Inh1 resulted in an almost global increase in IL-10 secretion on the conditions tested except for the T cells derived from dKO mice, which were insensitive to the presence of Inh 1 .
- secretion of IL-10 confirmed the effects of gradual inhibition of these enzymes and the specificity of the inhibitor.
- RECTIFIED SHEET (RULE 91 ) which are well known targets of TCPTP and PTP1 B.
- CTL carrying different genotypes were stimulated with IFN-y for 10 and 30 minutes and the levels phosphorylation were analyzed on the canonical dimerizing c-terminal phosphotyrosine residues by immunoblotting with specific antibodies.
- CRE control cells responded to IFN-y by increasing phosphorylation of these residues in STATs 1 , 2, 3, 4 and 5a (Fig. 10A, 10B and 10C) revealing the complexity of type I interferon signals in CD8 cells.
- dKO cells were largely different to controls at basal level as well, where protein expression and levels of phosphorylation were also affected. Particularly, and in opposition to STAT4, increased expression of STATs 1 and 3 was detected, accompanied with increased basal level phosphorylation of STAT3. Higher expression and basal phosphorylation of STAT3 was also seen in TCKO and TCKO/1 BHet samples, potentially related to the global changes in transcription seen in these cells.
- TCPTP/PTP1 B deficiency takes effect is the upregulation of transcription factor BatF3.
- BatF3 is linked to the differentiation of CD8+ dendritic cells into a phenotype with enhanced capacities to activate CD8+ T cells, named conventional DC type I (cDC1 ).
- cDC1 conventional DC type I
- the expression of was knocked down the expression of BatF3 using an siRNA during the in vitro differentiation of TCKO/1 BHet CTLs under the OT-1 background.
- RECTIFIED SHEET (RULE 91 ) enhanced effector genotype (Fig. 11 C). Immunoblotting confirmed an elevation of protein products for IRF4, Myb, ZEB and BLIMP1 , suggesting that transcriptomic changes observed between the different genotypes has a multifactorial origin.
- TCPTP and PTP1B have been associated with the control of proinflammatory signals not only in T cells, but also in other immune and non-immune cells. Indeed, it has been proposed that decreased activity of these phosphatases may be beneficial to antitumoral responses.
- the compound was injected in WT C57BL/6 mice bearing E.G7 thymoma.
- TCPTP and PTP1 B are ubiquitous enzymes with a broad range of activities involving several cytokine and growth factor receptor signals transduction. To avoid systemic side effects resulting from the use of Inh1, the compound was injected intratumorally, limiting its activity to the tumor microenvironment.
- E.G7 thymoma tumors were injected in WT C57BL/6 mice and their growth was monitored by caliper measurement. Tumors were injected with In hi from day 10 every 48 hours with an equivalent of 50 pM of the compound or with PBS (Fig. 12A). As expected, in PBS injected controls, tumor growth proceeded exponentially. Conversely, tumors injected with Inh1 maintained a similar size during the extent of the observations. Treatment with Inh1 clearly and unexpectedly limited tumor growth, potentially through cells intrinsic and immune mechanisms.
- EG.7 cells are engineered to express the exogenous antigen OVA, they can artificially contribute to the capacity of Inh1 to induce a targeting immune response.
- the syngeneic melanoma model B16F10 was used in the C57BL/6 background.
- the syngeneic melanoma model B16F10 is a tumor model known to be poorly immunogenic.
- Inh2 an alternative molecule from the same series of compounds as Inh1 , here in called Inhibitor 2 (Inh2), was used.
- I nh2 is disclosed in W02008089581 and the following formula:
- B16F10 melanoma is a “cold tumor” cancer model used to demonstrate the immunogenetic properties of immune checkpoint blockade therapies, including those based in anti-PD-1 antibodies with important clinical success.
- the compound and an anti-PD-1 monoclonal antibody were injected intratumorally as described above.
- the anti-PD-1 antibody used is the RMP1-14 monoclonal antibody which reacts with mouse PD-1 (also known as CD279) from BioXCell, Cat. No. BP0146.
- the present application shows the combined influence of the phosphatases PTP1B and TCPTP in CD8 T cell function, and their potential as immunotherapeutic targets.
- the effects of reduced expression of both genes in CD8T cells was studied.
- Double deleted mutant cells displayed a heavily modified phenotype resembling terminally differentiated effector T cells.
- These T cells made up to 80% of peripheral CD8 T cells in young unchallenged mice, suggesting that they were spontaneously activated, since control CRE expressing animals displayed only about 10% terminally differentiated effector T cells.
- Functional analysis supports the phenotypical findings as these T cells were highly cytotoxic against antigen specific target cells.
- IL-10 secretion correlated with the cytotoxic capacity of the T cells and with the level of inhibition of TCPTP / PTP1 B.
- IL-10 is classically regarded as an immunosuppressive cytokine, however recent literature highlights a role for this cytokine in reprograming metabolically exhausted CD8 T cells favoring antitumor responses [1], a potential mechanism involved in the enhanced antitumoral effects of TCPTP / PTP1 B inhibitors.
- Autocrine stimulation by the secreted IL-10 can also explain the increase of phosphorylated STAT3 seen after type I IFN stimulation of TCPTP / PTP1 B deficient cells, further reinforced by elevated expression of STAT3.
- the secretion pattern of IL-10 in the different cells analyzed suggests a commanding regulatory role for TCPTP in T cells as its deletion was required to observe an effect from PTP1 B inhibition/deletion. This opposes previous findings in macrophages [42], where PTP1 B deficiency alone caused increase of IL-10 production.
- the proinflammatory phenotype observed in TCPTP deficient cells has been explained by its regulatory role on IFN pathways, more specifically for its roles as a nuclear and cytoplasmic phosphatase for JAK1 and STAT1 [6, 19, 25], However, the data presented herein does not support dysregulation of IFN signals as a potential mechanism given that TCPTP I PTP1 B deficient cells experienced a reduction rather than increase of interferon response related genes.
- TCPTP / PTP1B inhibitors with already immune checkpoint inhibition therapies is an unexpected and surprising new therapeutic avenue. Indeed, synergy of TCPTP / PTP1 B inhibitors with an anti-PD-1 blockade model is shown herein. Furthermore, TCPTP / PTP1 B inhibition does not have to be T cells specific as effects in tumoral [19] and other immune components, as dendritic cells [7], promotes further antitumoral activity.
- PTP1 B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood, 2008. 112(10): p. 4098-4108.
- T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol, 2002. 12(6): p. 446-53.
- T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model and implications in human disease. Immunological Reviews, 2009. 228(1): p. 325-341 .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present document describes methods for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula (I) or Formula (II), or pharmaceutically acceptable salts thereof, and stereoisomers thereof, in combination with an immune checkpoint inhibitor, for the treatment of cancer.
Description
COMBINED INHIBITION OF TYROSINE PHOSPHATASES TCPTP AND PTP1B AND PD-1 BLOCKAGE IMMUNOTHERAPY IN THE TREATMENT OF CANCER
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority of United States Provisional Patent Application No. 63/343,662 filed on May 19th, 2022, the specification of which is hereby incorporated by reference in its entirety.
BACKGROUND
(a) Field
[0002] The subject matter disclosed generally relates to a method for the treatment of cancer, and more specifically to a method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula I, of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof, or combinations thereof, in combination with an immune checkpoint inhibitor.
(b) Related Prior Art
[0003] CD8 T cells are essential immune system components in mounting antitumoral responses [1], There is a positive correlation between the presence of CD8+ tumor infiltrating lymphocytes (TILs) and successful clinical outcomes in several types of cancer [8-10], Moreover, cancer regression is observed after clonal CD8+ cell repopulation in melanoma patients [11], setting the grounds for exploring CD8+ cell based therapies. Indeed, redirection and/or reactivation of immune responses against cancer has been a remarkable source for novel therapies as immune checkpoint blockade [12, 13], Immune checkpoint inhibitors (ICI) anti-PD-1 directed antibodies are extensively used for clinical trial and have been approved by the FDA for almost half of malignancies. They nevertheless still have a low estimated level of responsiveness of 12.5% and failed to increase life span or progression free survival significantly [14], Checkpoint inhibitors work by preventing/reversing a dysfunctional state of CD8 T cells known as exhaustion [15, 16], Exhausted CD8 T cells are the result of chronic activation and is characterized by the expression of several inhibitory receptors including CTLA-4, PD-1 , Tim-3, TIGIT, SLAMF6 [17], The limited success of ICI emphasizes the multifactorial nature of CD8 T cell dysfunction and encourage the search for novel strategies to prevent it. Indeed most of know checkpoint receptors act by modulating tyrosine phosphorylation through the recruitment of SHP-1 and SHP-2 phosphatases [17], Hence the role of other regulatory phosphatases needs to be explored.
[0004] TCPTP (PTPN2) and PTP1 B (PTPN1) are two highly homologous nonreceptor protein tyrosine phosphatases (NRPTP) with preferential activity on targets of the Jak/STAT pathway [2], While TCPTP role as immune regulator is known [3, 4, 18], recent studies have underscored the potential of this phosphatase as an immunotherapeutic target [7, 19-21], PTP1 B on the other hand, although less studied has been linked to an immune regulatory role [7, 22], Whilst substrate trapping mutant studies propose a mainly non-redundant role between both genes, PTP1 B targeting Jak2, Tyk 2 and STAT6 [23, 24] while TCPTP preferentially dephosphorylating Jak1 , Jak3, STAT 1 and STAT5 [25-27], attempts to block the genetic expression of both enzymes highlight a potential cooperative overlapping role in the phosphorylation of STAT 1 [6], Embryonic lethality of double deletion in mice strongly suggest this overlapping role, as single mutant animals reach birth at mendelian rates [28, 29],
[0005] To explore the potential synergy of both enzymes in CD8+ T cells, CD8+ cells from mice with conditionally targeted deletions of TCPTP and PTP1 b in mature CD8+ T cells are herein analyzed.
SUMMARY
[0006] According to an embodiment, there is provided a method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof:
Formula II wherein X’ is selected from CH and N;
R1’ is selected from the group consisting of (a) Ci-3alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OCi-3alkyl optionally substituted with 1- 3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -CN, (e) -HC=NOH, (f) -(CH3)C=NOH, (g) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens (i) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (j) -C(=O)NHR6’, (k) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, (I) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with
1-4 substituents independently selected from halogen and C 1 -2alkyl optionally substituted with 1-3 F, (m) Phenyl, (n) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (o) -CnC-Phenyl, and (p) -CH2-Phenyl, wherein the -CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen,
(ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci .galkyl optionally substituted with 1-3 halogens, (v) -OCi-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
R4’ and R5’ are each independently selected from the group consisting of:
(a) hydrogen;
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or C1-3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7and
(ix) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOXCH3, -SO2NH2, Ci.3 alkyl, Ci.3 haloalkyl, -OCi.3 alkyl, or -OC 1.3 haloalkyl;
or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C^jOC^ alkyl, (iii) -(C=O)OH,
alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, or Ci-3 haloalkyl;, and
R6’ is selected from the group consisting of H, Ci-3alkyl optionally substituted with 1-3 halogens, Phenyl, and -CH2-Phenyl, wherein Phenyl in both occurrences is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=0)0Ci-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci -3alkyl optionally substituted with 1-3 halogens, and (v) -OCi- 3alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of
alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -0C1-3 alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens,
alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2; in combination with an immune checkpoint inhibitor.
[0007] According to another embodiment, there is provided a method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula I, or pharmaceutically acceptable salts thereof, and stereoisomers thereof:
Formula I wherein:
X is selected from CH and N;
R1 is selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens,
-SO.C.^ alkyl, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; (f) -(C=O)NR5R6; and (g) aryl or heteroaryl wherein the aryl and heteroaryl group itself may be optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl optionally substituted with 1-3 halogens, (iii) -COOH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, (vii) -CN, and (viii) -SO2NH2;
R2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
R4 is selected from the group consisting of (a) H; (b)
alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -0C1 3 alkyl optionally substituted with 1- 3 halogens, -SOXC1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C^ alkyl or C1.3 haloalkyl;
R5 and R6 are independently selected from the group consisting of (a)
alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC^ alkyl optionally substituted with 1-3 halogens, -SOXC1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C^ alkyl or C^ haloalkyl;
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with 1-3 groups independently selected from (i) halogen, (ii) -(0=0)00^ alkyl, (iii) -(C=O)OH (iv) C^ alkyl optionally substituted with 1-3 halogens, (v) -0C1.3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, (vii) C1 3 hydroxyalkyl, (viii) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C 3 alkyl or C1 3 haloalkyl; and x is an integer from 0 to 2; in combination with an immune checkpoint inhibitor.
[0008] According to another embodiment, there is provided a method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a combination of a compound of structural Formula I and of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof:
Formula I
wherein:
X is selected from CH and N;
R1 is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, -SO^.3 alkyl, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; (f) -(C=O)NR5R6; and (g) aryl or heteroaryl wherein the aryl and heteroaryl group itself may be optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl optionally substituted with 1-3 halogens, (iii) -COOH (iv)
alkyl optionally substituted with 1-3 halogens, (v) -OC1-3 alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, (vii) -CN, and (viii) -SO2NH2;
R2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
R4 is selected from the group consisting of (a) H; (b) C1.3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1- 3 halogens, -SOXC1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C^ alkyl or C1.3 haloalkyl;
R5 and R6 are independently selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC^ alkyl optionally substituted with 1-3 halogens, -SOXC1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C^ alkyl or C^ haloalkyl;
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with 1-3 groups independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl, (iii) -(C=O)OH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -OC1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, (vii) C1 3 hydroxyalkyl, (viii) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C 3 alkyl or C^j haloalkyl; and x is an integer from 0 to 2;
wherein X’ is selected from CH and N;
R1’ is selected from the group consisting of (a) Ci^alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OC salkyl optionally substituted with 1- 3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -CN, (e) -HC=NOH, (f) -(CH3)C=NOH, (g) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens (i) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (j) -C(=O)NHR6’, (k) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, (I) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and C 1 -2alkyl optionally substituted with 1-3 F, (m) Phenyl, (n) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (0) -C^C-Phenyl, and (p) -CH2-Phenyl, wherein the -CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and Ci^alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen,
(ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci -3alkyl optionally substituted with 1-3 halogens, (v) -OCi-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
R4’ and R5’ are each independently selected from the group consisting of:
(a) hydrogen;
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or C1-3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7and
(ix) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOXCH3, -SO2NH2, Ci.3 alkyl, Ci.3 haloalkyl, -OCi.3 alkyl, or -OC 1.3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1.3 alkyl, (iii) -(C=O)OH,
alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, or Ci-3 haloalkyl;, and
R6’ is selected from the group consisting of H, Ci-3alkyl optionally substituted with 1-3 halogens, Phenyl, and -CH2-Phenyl, wherein Phenyl in both occurrences is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=0)0Ci-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Cvsalkyl optionally substituted with 1-3 halogens, and (v) -OCi- 3alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of C1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC^j alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, Ci-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2; in combination with an immune checkpoint inhibitor.
[0009] According to another embodiment, there is provided the use of a compound of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof, in combination with an immune checkpoint inhibitor, for the treatment of cancer:
R1’ is selected from the group consisting of (a) Ci-3alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OCi-3alkyl optionally substituted with 1- 3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -CN, (e) -HC=NOH, (f) -(CH3)C=NOH, (g) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens (i) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (j) -C(=O)NHR6’, (k) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, (I) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and Ci -2alkyl optionally substituted with 1-3 F, (m) Phenyl, (n) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (0) -C^C-Phenyl, and (p) -CH2-Phenyl, wherein the -CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci -3alkyl optionally substituted with 1-3 halogens, (v) -OCi-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
R4’ and R5’ are each independently selected from the group consisting of:
(a) hydrogen;
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or C1-3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7and
(ix) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOxCHs, -SO2NH2, C1-3 alkyl, C1-3 haloalkyl, -OC1-3 alkyl, or -OC 1-3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl, (iii) -(C=O)OH, (iv) C1 3 alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -OC1-3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, or Ci-3 haloalkyl;, and
R6’ is selected from the group consisting of H, Ci-3alkyl optionally substituted with 1-3 halogens, Phenyl, and -CH2-Phenyl, wherein Phenyl in both occurrences is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Cvsalkyl optionally substituted with 1-3 halogens, and (v) -OCi- 3alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of C1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC1 3 alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2.
[0010] According to another embodiment, there is provided use of a compound of structural Formula I, or pharmaceutically acceptable salts thereof, and stereoisomers thereof in combination with an immune checkpoint inhibitor for the treatment of cancer:
Formula I wherein:
X is selected from CH and N;
R1 is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1-3 alkyl optionally substituted with 1-3 halogens, -SO.C.^ alkyl, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; (f) -(C=O)NR5R6; and (g) aryl or heteroaryl wherein the aryl and heteroaryl group itself may be optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl optionally substituted with 1-3 halogens, (iii) -COOH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -OC1 3 alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, (vii) -CN, and (viii) -SO2NH2;
R2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
R4 is selected from the group consisting of (a) H; (b) C1.3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1- 3 halogens, -SOXC1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C^ alkyl or C1.3 haloalkyl;
R5 and R6 are independently selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC^ alkyl optionally substituted with 1-3 halogens, -SOXC1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C^ alkyl or C^ haloalkyl;
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with 1-3 groups independently selected from (i) halogen, (ii) -(0=0)00^ alkyl, (iii) -(C=O)OH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -0C1.3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, (vii) C^ hydroxyalkyl, (viii) aryl or
heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C 3 alkyl or C1 3 haloalkyl; and x is an integer from 0 to 2.
[0011] According to another embodiment, there is provided the use of a combination of a compound of structural Formula I and of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof in combination with an immune checkpoint inhibitor for the treatment of cancer:
Formula I wherein:
X is selected from CH and N;
R1 is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1 -5 halogens and optionally with one group selected from -OH, -OC1-3 alkyl optionally substituted with 1-3 halogens, -SO.C.^ alkyl, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; (f) -(C=O)NR5R6; and (g) aryl or heteroaryl wherein the aryl and heteroaryl group itself may be optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl optionally substituted with 1-3 halogens, (iii) -COOH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -OC1 3 alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, (vii) -CN, and (viii) -SO2NH2;
R2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
R4 is selected from the group consisting of (a) H; (b) C1.3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1-3 alkyl optionally substituted with 1- 3 halogens, -SOXC1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C^ alkyl or C1.3 haloalkyl;
R5 and R6 are independently selected from the group consisting of (a)
alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC^ alkyl optionally substituted with 1-3 halogens, -SOXC1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C^ alkyl or C^ haloalkyl;
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with 1-3 groups independently selected from (i) halogen, (ii) -(C^jOC^ alkyl, (iii) -(C=O)OH (iv)
alkyl optionally substituted with 1-3 halogens, (v) -OC1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, (vii) C1 3 hydroxyalkyl, (viii) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C 3 alkyl or C1.3 haloalkyl; and x is an integer from 0 to 2;
wherein X’ is selected from CH and N;
R1’ is selected from the group consisting of (a) Ci-3alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OCi-3alkyl optionally substituted with 1- 3 halogens, -SOxCi-3alkyl, and -ON, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -ON, (e) -HC=NOH, (f) -(CH3)C=NOH, (g) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens (i) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (j) -C(=O)NHR6’, (k) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, (I) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and Ci -2alkyl optionally substituted with 1-3 F, (m) Phenyl, (n) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (0) -C^C-Phenyl, and (p) -CH2-Phenyl, wherein the -CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci -3alkyl optionally substituted with 1-3 halogens, (v) -OCi-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
R4’ and R5’ are each independently selected from the group consisting of:
(a) hydrogen;
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C-|-3 alkyl, or C1.3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7and
(ix) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOxCHs, -SO2NH2, C1-3 alkyl, C1-3 haloalkyl, -OC1-3 alkyl, or -OC 1-3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(0=0)00^ alkyl, (iii) -(C=O)OH,
alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, alkyl, or Ci-3 haloalkyl; and
R6’ is selected from the group consisting of H, Ci^alkyl optionally substituted with 1-3 halogens, Phenyl, and -CH2-Phenyl, wherein Phenyl in both occurrences is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=0)0Ci-3alkyl optionally substituted
with 1-3 halogens, (iii) -C(=O)OH (iv) Ci .galkyl optionally substituted with 1-3 halogens, and (v) -OCi- 3alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of C1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC1 3 alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COCH, and -OC1.3 alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2.
[0012] The compound of formula II may be of structural Formula Ila, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
Ila wherein
R1’ is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OCi-3alkyl optionally substituted with 1-3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -HC=NOH, (e) -(CH3)C=NOH, (f) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (g) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -C(=O)OCi.3alkyl optionally substituted with 1-3 halogens, (i) -C(=O)NHR6’, (j) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and Ci.2alkyl optionally substituted with 1-3 F, (k) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and C1.2 alkyl optionally substituted with 1-3 F, (I) Phenyl, (m) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (n) -C^C-Phenyl, (0) -CH2-Phenyl, and (p) -CN, wherein the - CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and C1-2 alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are
optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi. salkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH, (iv) Ci-3alkyl optionally substituted with 1-3 halogens, (v) -OCi-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R3’ is halogen;
R4 and R5 are each independently selected from the group consisting of:
(a) hydrogen:
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or C1-3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7, and
(xiii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOxCHs, -SO2NH2, C1-3 alkyl, C1-3 haloalkyl, -OC1-3 alkyl, or -OC 1-3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(0=0)00^3 alkyl, (iii) -(C=O)OH, (iv)
alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, or Ci_3 haloalkyl;
R6 is selected from the group consisting of H,
alkyl optionally substituted with 1-3 halogens, phenyl, or -CH2-phenyl, wherein phenyl is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(0=0)00^ alkyl optionally substituted with 1-3
halogens, (iii) -COOH, (iv)
alkyl optionally substituted with 1-3 halogens, and (v) -OC1-3 alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of
alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -OC1 3 alkyl, (iii) aryl, and (iv) heteroaryl, wherein wherein the aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2.
[0013] The compound may be selected from the following compounds:
or a pharmaceutically acceptable salt thereof.
[0016] The compound of Formula I may be of structural Formula la, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
wherein:
R1 is selected from the group consisting of (a)
alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1-3 alkyl optionally substituted with 1-3 halogens, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; and (f) -(C=O)NR5R6;
R4 is selected from the group consisting of (a) H; and (b) C1 3 alkyl optionally substituted with 1-5 halogens;
R5 and R6 are independently selected from the group consisting of c1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC1 3 alkyl optionally substituted with 1-3 halogens; and
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i)
halogen, (ii) alkyl optionally substituted with 1-3 halogens, (iii) -OC^ alkyl optionally substituted with 1-3 halogens, (iv) -OH, and (vii) C1 3 hydroxyalkyl.
[0017] The compound of formula I may be of structural Formula lb, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
wherein:
R1 is selected from the group consisting of (a)
alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; and (f) -(C=O)NR5R6;
R4 is selected from the group consisting of (a) H; and (b)
alkyl optionally substituted with 1-5 halogens;
R5 and R6 are independently selected from the group consisting of C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC^j alkyl optionally substituted with 1-3 halogens; and
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i) halogen, (ii) C1 3 alkyl optionally substituted with 1-3 halogens, (iii) -OC1 3 alkyl optionally substituted with 1-3 halogens, (iv) -OH, and (vii)
hydroxyalkyl.
[0019] The immune checkpoint inhibitor may be an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or molecular inhibitors of these receptors.
[0020] The anti-PD-1 antibody may be selected from the group consisting of nivolumab antibody, pembrolizumab antibody, pidilizumab antibody, cemiplimab antibody, dostarlimab antibody, JTX-4014 antibody, Spartalizumab antibody, Camrelizumab antibody, Sintilimab antibody, Tislelizumab antibody, Toripalimab antibody, INCMGA00012 antibody, AMP-224 antibody, AMP-514 antibody, RMP1-14 antibody or combinations thereof.
[0021] The anti-PDL-1 antibody may be selected from the group consisting of B7-H1 antibody, BMS-936559 antibody, MPDL3280A (atezolizumab) antibody, MEDI-4736 antibody, MSB0010718C antibody, 10F-9G2 antibody, avelumab antibody, durvalumab antibody, or combinations thereof.
[0022] The anti-CTLA-4 antibody may be selected from the group consisting of ipilimumab or tremelimumab or combinations thereof.
[0023] The administration of the compound of structural Formula I orstructural Formula II may be an intratumoral administration.
[0024] The administration of the compound of structural Formula I or structural Formula II is an oral administration.
[0025] The administration of the immune checkpoint inhibitor may be a systemic administration, and intratumoral administration, or a combination thereof.
[0026] The administration of the compound of structural Formula I orstructural Formula II may be an intratumoral administration and administration of the immune checkpoint inhibitor may be a systemic administration, and intratumoral administration, or a combination thereof, or administration of the compound of structural Formula I may be an intratumoral administration and administration of the immune checkpoint inhibitor may be a systemic administration, an intratumoral administration, or a combination thereof, or administration of the compound of structural Formula I may be an oral administration and administration of the immune checkpoint inhibitor may be a systemic administration, an intratumoral administration, or a combination thereof.
[0027] The compound of structural Formula I or structural Formula II may be administered first, and the immune checkpoint inhibitor is administered second.
[0028] The cancer may be a solid tumor, a prostate cancer, a breast cancer, a brain cancer, a glioma, a lung cancer, a salivary cancer, a stomach cancer, a thymic epithelial cancer, a thyroid cancer, an ovarian cancer, a multiple myeloma, a leukemia, a melanoma, a lymphoma, a gastric cancer, a kidney cancer, a pancreatic cancer, a bladder cancer, a colon cancer and a liver cancer.
[0029] The method or the use of the present invention may further comprise monitoring the activity of the compound of structural Formula I, structural Formula II or both structural Formula I and structural Formula II.
[0030] The following terms are defined below.
[0031] The term “antibody”, which is also referred to in the art as “immunoglobulin” (Ig), as used herein refers to a protein constructed from paired heavy and light polypeptide chains; various Ig isotypes exist, including IgA, IgD, IgE, IgG, and IgM. When an antibody is correctly folded, each chain
folds into a number of distinct globular domains joined by more linear polypeptide sequences. For example, the immunoglobulin light chain folds into a variable (VL) and a constant (CL) domain, while the heavy chain folds into a variable (VH) and multiple constant (e.g., CHI, CH2, CHS) domains. Interaction of the heavy and light chain variable domains (VH and L) results in the formation of an antigen binding region (Fv). Each domain has a well-established structure familiar to those of skill in the art.
[0032] The present invention further encompasses “monoclonal antibodies” (mAb). Monoclonal antibodies are antibodies that are made by identical immune cells which are all clones belonging to a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody).
[0033] Features and advantages of the subject matter hereof will become more apparent in light of the following detailed description of selected embodiments, as illustrated in the accompanying figures. As will be realized, the subject matter disclosed and claimed is capable of modifications in various respects, all without departing from the scope of the claims. Accordingly, the drawings and the description are to be regarded as illustrative in nature, and not as restrictive and the full scope of the subject matter is set forth in the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Further features and advantages of the present disclosure will become apparent from the following detailed description, taken in combination with the appended drawings, in which:
[0035] Fig. 1A illustrates that CD8 T cells activation and differentiation is increased in naive mice with reduced expression of TCPTP and/or PTP1 B. Ex vivo analysis of peripheral T cells population of naive 6 to 8 weeks old mice with conditional deletions of Ptpnl and/or Ptpn2 in CD8 T cells by multiparametric flow cytometric analysis of T cells from spleen and lymph nodes. The panels show the CD4 vs CD8 cells from different genotypes. Events shown correspond to single, viable and lineage negative (Lin-) gates.
[0036] Fig. 1 B shows that statistical representation of T cell subtypes from different experiments organized by genotype.
[0037] Fig. 1C shows histogram representation of T cell subtypes from different experiments organized by genotype.
[0038] Fig. 1 D shows the quantification of CD8 low populations in spleen of different genotypes.
[0039] Fig. 1E shows dot plots of CD8 T cell differentiation determined by CD62L and CD44 expression. Fig. 1 F shows the statistical representation of CD8 T cell differentiation determined by CD62L and CD44 expression.
[0040] Fig. 1G a histogram representation of differentiation markers EOMES, KLRG1 and CD127. (CRE n=4, 1 BKO n=2, TCKO n=4, TCKO/1 BHet n=2, dKO n=4) (Bars represent ± S.E.M.; Two way ANOVA; P values *<0.05, **<0.005, ***<0.0005, ****<0.00005).
[0041] Fig. 1H shows the quantification of differentiation markers EOMES, KLRG1 and CD127. (CRE n=4, 1 BKO n=2, TCKO n=4, TCKO/1 BHet n=2, dKO n=4) (Bars represent ± S.E.M.; Two way ANOVA; P values *<0.05, **<0.005, ***<0.0005, ****<0.00005).
[0042] Fig. 2A illustrates the conditional deletion ofTCPTP and PTP1 B in CD8 T cells. Shown is an immunoblot for TCPTP, PTP1 B and Calnexin as loading control from protein homogenates of CD4 and CD8 T cells with different genotypes analyzed.
[0043] Fig. 2B illustrates the thymus size, expressed as weight, from 8-12-week-old male mice carrying the different genotypes analyzed.
[0044] Fig. 2C illustrates the hematoxylin and eosin staining of thymus sections from 10-week- old CRE controls orTCPTP/PTP1 B (dKO) CD8 specific “knockouts”.
[0045] Fig. 2D shows spleen and inguinal lymph node size (by weight) and cellularity from the different genotypes analyzed.
[0046] Fig. 2E shows the total number of CD4 and CD8 T cells from spleen and inguinal lymph nodes shown in Fig. 1 B.
[0047] Fig. 3A illustrates that mouse CD8 T cells deficient in TCPTP and/or PTP1 B are more cytotoxic and reach terminal differentiation. OT-1 CD8 T cells with different Ptpnl and/or Ptpn2 deletions were activated/expanded with aCD3/aCD28 antibodies and IL-2. Day 5 cells were tested for specific cytotoxicity against the OVA expressing E.G7 thymoma cells.
[0048] Fig. 3B shows statistical representation of several experiments from Fig. 3A.
[0049] Fig. 3C shows ELISA quantification of IFN-y in supernatants from Fig. 3A.
[0050] Fig. 3D shows flow cytometry plots of CD8 T cell differentiation determined by CD62L and CD44 expression.
[0051] Fig. 3E shows bar representation of percentages of CD8 T cell differentiation determined by CD62L and CD44 expression.
24
RECTIFIED SHEET (RULE 91 )
[0052] Fig. 4 illustrates the in vitro cytotoxicity against specific target cells of CD8 T cells with genetic deficiency of TCPTP and/or PTP1 B. Statistical representation of day 5 CTLs from all the different genotypes tested for specific cytotoxicity against the OVA expressing E.G7 thymoma cells.
[0053] Fig. 5A Illustrates that pharmacological inhibition of TCPTP and PTP1 B results in enhanced cytotoxicity and effector differentiation. CD8 T cells from OT-1 mice were activated/expanded by aCD3/aCD28 antibodies and IL-2 in the presence of different concentrations of TCPTP/PTP1 B inhibitor (I n h 1 ) for 5 days. Specific cytotoxicity against OVA expressing E.G7 thymoma cells was measure.
[0054] Fig. 5B shows the statistical representation of several experiments as per Fig. 5A (n=4).
[0055] Fig. 5C shows the ELISA quantification of IFN-y in supernatants from Fig. 5A.
[0056] Fig. 5D shows flow cytometry plots of CD8 T cell differentiation determined by CD62L and CD44 expression.
[0057] Fig. 5E shows bar representation of percentages of CD8 T cell differentiation determined by CD62L and CD44 expression.
[0058] Fig. 5F shows the cytotoxicity of CD8 T cells from animals with different TCPTP and PTP1B genotypes, additionally treated with Ihn1.
[0059] Fig. 5G shows ELISA quantification of IFN-y in supernatants from Fig. 5F. In each panel bars represent ± S.E.M.; Two-way ANOVA; P values *<0.05, **<0.005, ***<0.0005, ****<0.00005).
[0060] Fig. 6A illustrates that pharmacological inhibition of TCPTP and PTP1 B in human T cells results in enhanced proinflammatory cytokine secretion and Tern differentiation. Purified T cells from human donors were activated by aCD3/aCD28 and analyzed at day 7 for IFN-y and TNF-a by flow cytometry. Shown are plots of cells gated in CD4 and CD8 populations distributed by IFN-y and TNF-a expression.
[0061] Fig. 6Bshows bar graphs showing statistical representation of 2 biological replicates for CD4 and CD8 populations distributed by IFN-y expression.
[0062] Fig. 6C shows bar graphs showing statistical representation of 2 biological replicates for CD4 and CD8 populations distributed by TNF-a expression.
[0063] Fig. 6D shows bar graphs presenting the percentage of Effector Memory T cell (Tern) and Central memory T cell (Tern) based on the selection of CD45 RO high and CD62L high ratio with orwithout inh 1 in CD4 and CD8 T cells.
25
RECTIFIED SHEET (RULE 91 )
[0064] Fig. 7A illustrates the pharmacological inhibition of TCPTP and PTP1B in human T cells. Normalized percentual representation of experiments in Fig. 5 showing IFN-y.
[0065] Fig. 7B illustrates the pharmacological inhibition of TCPTP and PTP1B in human T cells. Normalized percentual representation of experiments in Fig. 5 showing TNF-a.
[0066] Fig. 7C shows the percentual contribution of CD4 and CD8 T cells of in vitro human T cell cultures at day 7.
[0067] Fig. 8A illustrates the bulk mRNA analysis of CD8 T cells deficient in TCPTP and/or PTP1B or treated with Inh1. Heatmap of genes differentially expressed in the genotypes analyzed is shown. Organized as opposing expression between TCKO/1BHet CD8 T cells and CRE controls. Overexpressed genes showed as gradual red shift, under expressed genes as gradual blue shift.
[0068] Fig. 8B illustrates a volcano plot illustrating the significant differentially expressed genes between TCKO and TCKO/1B Het CD8 cells (FDR 5%).
[0069] Fig. 8C illustrates a dot plot corresponding to selected list of genes with relevancy to CD8 T cells, activation/differentiation. Overexpressed genes showed as gradual red shift, under expressed genes as gradual blue shift.
[0070] Fig. 9A illustrates bulk mRNA analysis of CD8 T cells deficient in TCPTP and/or PTP1 B or treated with Inh 1. Volcano plots representing the significant differentially expressed genes between day 5 CTLs from CRE controls and the different genotypes analyzed.
[0071] Fig. 9B illustrates the significant differentially expressed genes between day 5 CTLs form C57BL/6 mice, treated or not with 5 pM I nh 1 .
[0072] Fig. 9C illustrates the differential expression of the different members of the NR4A transcription factor family from samples in A) and B).
[0073] Fig. 9D illustrates the secretion of IL-10 from CTLs carrying different TCPTP and PTP1B mutations, treated or not with 5 pM Inh1. Determined by ELISA from supernatants form Fig. 1 F.
[0074] Fig. 10A illustrates the global changes of STAT expression and phosphorylation in CD8T cells with reduced or absent TCPTP/PTP1B activity. Shown is an immunoblot of day 5 CTLs stimulated with rmIFN-p for the indicated times.
[0075] Fig. 10B illustrates the global changes of STAT expression and phosphorylation in CD8T cells with reduced or absent TCPTP/PTP1B activity. Shown is an immunoblot of day 5 CTLs stimulated with rmIFN-p for the indicated times.
26
RECTIFIED SHEET (RULE 91 )
[0076] Fig. 10C illustrates the global changes of STAT expression and phosphorylation in CD8T cells with reduced or absent TCPTP/PTP1 B activity. Shown is a representation of densitometric analysis. (Representative of at least 3 experiments).
[0077] Fig. 11A illustrates the increased expression of transcription factors in CD8T cells with reduced or absent TCPTP/PTP1B activity. Shown is the specific cytotoxicity against OVA expressing E.G7 thymoma cells from 5-day TCKO/1BHet CTLs transfected with no target or BATF3 siRNAs.
[0078] Fig. 11 B illustrates an immunoblot with specific BATF3 and calnexin antibodies to demonstrated specific deletion.
[0079] Fig. 11C illustrates an immunoblot analysis of cell homogenates from the different CTL genotypes analyzed, probed with antibodies for several transcription factors.
[0080] Fig. 12A illustrates that TCPTP / PTP1 B pharmacological inhibitors have similar affinity for both enzymesand that intratumoral injection of Inh1 results in tumor regression. Shown is a timeline of tumor volume after subcutaneous injection of 3 x 105 EG.7 OVA expressing thymoma cells in C57BL/6 mice. Mice were subjected to treatment by intratumoral injection of equivalent to 50 pM I nh1 every 2 days, or PBS as control. (Shown one of two experiments).
[0081] Fig. 12B illustrates the in vitro phosphatase activity of TCPTP and PTP1B catalytic domains in presence of increasing concentrations of In h 1 and Inh2. Table at right shows average IC50 from 3 experiments.
[0082] Fig. 12C illustrates the specific cytotoxicity against OVA expressing E.G7 thymoma cells from 5-day C57BL/6 CTLs treated with Inh1 or Inh2 at the concentrations specified, (one of three experiments shown).
[0083] Fig. 13A illustrates that the TCPTP / PTP1 B pharmacological inhibition synergize with anti-PD-1 antibodies to restrict B16F10 melanoma tumor growth in vivo. Shown is a timeline of tumor volume after subcutaneous injection of 1.5 x 105 B16F10 melanoma cells in C57BL/6 mice. Mice were subjected to treatment either with anti-PD-1 mAb (a-PD1 ) (n=3), TCPTP / PTP1 B inhibitor (Inh2) (n=5), both (n=5) or none (n=5).
[0084] Fig. 13B illustrates the statistical comparison of all groups for experiment A) (Tukey’s multiple comparison test with 95% confidence intervals).
[0085] Fig. 13C illustrates survival curve determined by humane endpoint intervention. (Data from one of two independent experiments).
27
RECTIFIED SHEET (RULE 91 )
[0086] Fig. 14A illustrates an immunoblotting analysis of Statl phosphorylation in PBMC of C57BL/6 mice after 2 hours of intraperitoneal injection of Inh2.
[0087] Fig 14B illustrates an immunoblotting analysis of Stat3 phosphorylation in PBMC of C57BL/6 mice after 2 hours of intraperitoneal injection of Inh2.
DETAILED DESCRIPTION
[0088] Compounds of Formula I and/or Formula II are inhibitors of both PTPN1 (PTP1 B) and PTPN2 (TCPTP). T lymphocytes deficient in TCPTP, or deficient in TCPTP and additionally hemideficiency of PTP1B display enhanced pro-cytotoxic abilities. Small molecule inhibitors targeting specifically both the PTP1 B and TCPTP enzymes showed a remarkable enhancement of treated CD8 T cells in mouse and human cells, providing therapeutic use in solid tumors.
[0089] According to an embodiment, the present invention relates to a method for the treatment of cancer by administering a therapeutically effective amount of a compound of structural Formula I, of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof, or combinations thereof, in combination with an immune checkpoint inhibitor, to a subject in need thereof.
[0090] According to another embodiment, the present invention relates to a method for the treatment of PTP1 B and TCPTP dependent diseases, such as for example cancer, by administering a therapeutically effective amount of a compound of structural Formula I, of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof, or combinations thereof, in combination with an immune checkpoint inhibitor, to a subject in need thereof.
[0091] Types of cancer that may be treated by compounds of the present invention include, but are not limited to, prostate cancer, breast cancer, brain cancer, glioma, lung cancer, salivary cancer, stomach cancer, thymic epithelial cancer, thyroid cancer, ovarian cancer, multiple myeloma, leukemia, melanoma, lymphoma, gastric cancer, kidney cancer, pancreatic cancer, bladder cancer, colon cancer and liver cancer.
Abbreviations
[0092] Abbreviations and terms that are commonly used in the fields of organic chemistry, medicinal chemistry, pharmacology, and medicine and are well known to practitioners in these fields are used herein. Representative abbreviations and definitions are provided below:
[0093] Ac is acetyl [CH3C(O)-], AC2O is acetic anhydride; ACN is acetontrile; APC is antigen- presenting cell; Aik is alkyl; Ar is aryl; 9-BBN is 9-borabicyclo[3.3.1]nonane; Bn is benzyl; BOC is tert Butyloxycarbonyl; br is broad; CH2CI2 is dichloromethane; d is doublet; DBU is 1 ,8-
28
RECTIFIED SHEET (RULE 91 )
diazabicyclo[5.4.0]undec-7-ene; DC is dendritic cell; DEAD is diethyl azodicarboxylate; DIAD is diisopropylazodicarboxylate; DIBAL is diisobutylaluminum hydride; DIPEA is N,N- diisopropylethylamine; DMF is N,N-dimethylformamide; DMSO is dimethyl sulfoxide; EDAC (or EDC) is 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide HCI; ESI is electrospray ionization; EtsN is triethylamine; Et is ethyl; EtOAc is ethyl acetate; EtOH is ethanol; 3-F-Ph is 3-fluorophenyl; h is hours; HATU is O-(7-azabenzotriazol-1-yl)-/V,/V,/V’,/\/’-tetramethyluronium hexafluorophosphate; HOAc is acetic acid; HCI is hydrochloric acid; HOBt is 1 -hydroxybenzotriazole; HPLC is high performance liquid chromatography; Hunig’s base is diisopropylethylamine; LiOH is lithium hydroxide; LCMS is HPLC with mass Spectral detection; LG is leaving group; m is multiplet; M is molar; mmol is millimole; Me is methyl; MeCN is acetonitrile; MeOH is methanol; MeTHF is 2-methyltetrahydrofuran; MgSO4 is magnesium sulfate; min is minutes; MS is mass spectroscopy; MsCI is methanesulfonyl chloride; MTBE is methyl tert-butyl ether; N is normal; NaHMDS is sodium hexamethyldisiliazide; NaOAc is sodium acetate; NaOH is sodium hydroxide; NaOtBu is sodium tert-butoxide; Na2SO4is sodium sulfate; NMO is N-methylmorpholine N oxide; NMP is N Methyl pyrrolidinone; NMR is nuclear magnetic resonance spectroscopy; Pd(dba)2 is tris(dibenzylideneacetone)dipalladium; PdCh(Ph3P)2 is dichlorobis-(triphenylphosphene) palladium; PG Denotes an unspecified protecting group; Ph is phenyl; PhMe is toluene; PPhs is triphenylphosphine; PMB is para-methoxybenzyl; RT is room temperature; s is singlet; t is triplet; TBAF is tetrabutyl ammonium fluoride; TBS is tertbutyldimethylsilyl; tBu is tert-butyl; Tf is triflate; TFA is trifluoroacetic acid; TFAA is trifluoroacetic anhydride; THF is tetra hydrofuran; TLC is thin layer chromatography; TMEDA is N,N,N',N'- tetramethylethylenediamine; TMS is trimethylsilyl; TPAP is tetrapropylammonium perruthenate.
Definitions
[0094] “Alkyl”, as well as other groups having the prefix “alk”, such as alkoxy and alkanoyl, means carbon chains which may be linear or branched, and combinations thereof, unless the carbon chain is defined otherwise. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like. Where the specified number of carbon atoms permits, e.g., from C3-10, the term alkyl also includes cycloalkyl groups, and combinations of linear or branched alkyl chains combined with cycloalkyl structures. When no number of carbon atoms is specified, C1-6 is intended.
[0095] “Cycloalkyl” is a subset of alkyl and means a saturated carbocyclic ring having a specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. A cycloalkyl group generally is monocyclic unless stated otherwise. Cycloalkyl groups are saturated unless otherwise defined.
29
RECTIFIED SHEET (RULE 91 )
[0096] The term “alkoxy” refers to straight or branched chain alkoxides of the number of carbon atoms specified (e.g., C1-6 alkoxy), or any number within this range [i.e., methoxy (MeO-), ethoxy, isopropoxy, etc.].
[0097] The term “alkylthio” refers to straight or branched chain alkylsulfides of the number of carbon atoms specified (e.g., C1-6 alkylthio), or any number within this range [i.e., methylthio (MeS-), ethylthio, isopropylthio, etc.].
[0098] The term “alkylamino” refers to straight or branched alkylamines of the number of carbon atoms specified (e.g., C1-6 alkylamino), or any number within this range [i.e., methylamino, ethylamino, isopropylamino, t-butylamino, etc.].
[0099] The term “alkylsulfonyl” refers to straight or branched chain alkylsulfones of the number of carbon atoms specified (e.g., C1-6 alkylsulfonyl), or any number within this range [i.e., methylsulfonyl (MeSO2_), ethylsulfonyl, isopropylsulfonyl, etc.].
[00100] The term “alkylsulfinyl” refers to straight or branched chain alkylsulfoxides of the number of carbon atoms specified (e.g., C-i-6 alkylsulfinyl), or any number within this range [i.e., methylsulfinyl (MeSO-), ethylsulfinyl, isopropylsulfinyl, etc.].
[00101] The term “alkyloxycarbonyl” refers to straight or branched chain esters of a carboxylic acid derivative of the present invention of the number of carbon atoms specified (e.g., C-i-e alkyloxycarbonyl), or any number within this range [i.e., methyloxycarbonyl (MeOCO ), ethyloxycarbonyl, or butyloxycarbonyl].
[00102] “Aryl” means a mono- or polycyclic aromatic ring system containing carbon ring atoms. The preferred aryls are monocyclic or bicyclic 6-10 membered aromatic ring systems. Phenyl and naphthyl are preferred aryls. The most preferred aryl is phenyl.
[00103] “Heterocyclyl" refer to saturated or unsaturated non-aromatic rings or ring systems containing at least one heteroatom selected from O, S and N, further including the oxidized forms of sulfur, namely SO and SO2. Examples of heterocycles include tetra hydrofuran (THF), dihydrofuran,
1.4-dioxane, morpholine, 1 ,4-dithiane, piperazine, piperidine, 1 ,3-dioxolane, imidazolidine, imidazoline, pyrroline, pyrrolidine, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1 ,3-dioxane, 1 ,3-dithiane, oxathiane, thiomorpholine, 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxoazetidin-1-yl,
1 .2.4-oxadiazin-5(6H)-one-3-yl, and the like.
[00104] "Heteroaryl" means an aromatic or partially aromatic heterocycle that contains at least one ring heteroatom selected from O, S and N. Heteroaryls thus include heteroaryls fused to other kinds of rings, such as aryls, cycloalkyls and heterocycles that are not aromatic. Examples of heteroaryl
30
RECTIFIED SHEET (RULE 91 )
groups include: pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl (in particular, 1 ,3,4-oxadiazol-2-yl and 1 ,2,4-oxadiazol-3-yl), thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, triazinyl, thienyl, pyrimidyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzofuranyl, indolinyl, pyridazinyl, indazolyl, isoindolyl, dihydrobenzothienyl, indolizinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, carbazolyl, benzodioxolyl, quinoxalinyl, purinyl, furazanyl, isobenzylfuranyl, benzimidazolyl, benzofuranyl, benzothienyl, quinolyl, indolyl, isoquinolyl, dibenzofuranyl, and the like. For heterocyclyl and heteroaryl groups, rings and ring systems containing from 3-15 atoms are included, forming 1-3 rings.
[00105] “Halogen” refers to fluorine, chlorine, bromine and iodine. Chlorine and fluorine are generally preferred. Fluorine is most preferred when the halogens are substituted on an alkyl or alkoxy group (e.g. CF3O and CF3CH2O).
[00106] The term « composition » as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Such term in relation to pharmaceutical composition is intended to encompass a product comprising the active ingredient(s) and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier. By "pharmaceutically acceptable" or “acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
[00107] The terms « T cell(s) », « T lymphocyte(s) », « T cell product(s) » as used herein are intended to encompass isolated tumor-infiltrating lymphocyte (TIL), T cell receptor (TCR) engineered cell, and/or chimeric antigen receptor (CAR) engineered cell isolated by the method of the present invention. It also includes different memory T cell populations such as Stem central memory TSCM cells, Central memory TCM cells and Effector memory TEM cells, that are beneficial to mount and maintain surveillance and Immune response.
[00108] The terms “PTPN1” as used herein is intended to mean the tyrosine-protein phosphatase non-receptor type 1 , also known as protein-tyrosine phosphatase 1B (PTP1 B), and is an enzyme that is the founding member of the protein tyrosine phosphatase (PTP) family. In humans it is encoded by the PTPN1 gene. PTP1 B is a negative regulator of the insulin signaling pathway and is
31
RECTIFIED SHEET (RULE 91 )
considered a promising potential therapeutic target, in particular for treatment of type 2 diabetes. It has also been implicated in the development of breast cancer and has been explored as a potential therapeutic target in that avenue as well.
[00109] The terms “PTPN2” as used herein is intended to mean the tyrosine-protein phosphatase non-receptor type 2, also known as T-cell protein-tyrosine phosphatase (TCPTP, TC- PTP), and in humans is encoded by the PTPN2 gene.
[00110] The present invention uses compounds of structural Formula I, or of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof, or combinations thereof. The compounds structural Formula I are the following:
wherein:
X is selected from CH and N;
R1 is selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, -SOXC^ alkyl, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; (f) -(C=O)NR5R6; and (g) aryl or heteroaryl wherein the aryl and heteroaryl group itself may be optionally substituted with 1 -3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl optionally substituted with 1 -3 halogens, (iii) -COOH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -OC1 3 alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, (vii) -CN, and (viii) -SO2NH2;
R2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
R4 is selected from the group consisting of (a) H; (b) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1- 3 halogens, -SOXC1 3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C1 3 alkyl or C1 3 ha loa I ky I;
32
RECTIFIED SHEET (RULE 91 )
R5 and R6 are independently selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, -SOXC1-3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C1 3 alkyl or C1 3 haloalkyl;
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with 1 -3 groups independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl, (iii) -(C=O)OH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -OC1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, (vii) C1 3 hydroxyalkyl, (viii) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C^ 3 alkyl or C1 3 haloalkyl; and x is an integer from 0 to 2.
[00111] The compounds of structural formula I include compounds of structural Formula la, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
wherein:
R1 is selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; and (f) -(C=O)NR5R6;
R4 is selected from the group consisting of (a) H; and (b) C1 3 alkyl optionally substituted with 1 -5 halogens;
R5 and R6 are independently selected from the group consisting of C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC1 3 alkyl optionally substituted with 1-3 halogens; and
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i)
RECTIFIED SHEET (RULE 91 )
halogen, (ii) C1 3 alkyl optionally substituted with 1 -3 halogens, (iii) -OC1 3 alkyl optionally substituted with 1 -3 halogens, (iv) -OH, and (vii) C1 3 hydroxyalkyl.
[00112] The compounds of structural formula I include compounds of structural Formula lb, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
wherein:
R1 is selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; and (f) -(C=O)NR5R6;
R4 is selected from the group consisting of (a) H; and (b) C1 3 alkyl optionally substituted with 1 -5 halogens;
R5 and R6 are independently selected from the group consisting of C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC1 3 alkyl optionally substituted with 1-3 halogens; and
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i) halogen, (ii) C1 3 alkyl optionally substituted with 1 -3 halogens, (iii) -OC1 3 alkyl optionally substituted with 1 -3 halogens, (iv) -OH, and (vii) C1 3 hydroxyalkyl.
[00113] The compounds of structural Formula I may be compounds selected from the following compounds:
RECTIFIED SHEET (RULE 91 )
[00114] The compounds structural Formula II are the following:
35
RECTIFIED SHEET (RULE 91 )
Formula II wherein X’ is selected from CH and N;
R1’ is selected from the group consisting of (a) Ci -3a Iky I optionally substituted with 1- 3 halogens and optionally with one group selected from -OH, -OC-|-3alkyl optionally substituted with 1-3 halogens, -SOxCi .salkyl, and -CN, (b) -C(=O)H, (c) -C(=O)C-|_3alkyl optionally substituted with 1- 3 halogens, (d)-CN, (e) -HC=NOH, (f) -(CH3)C=NOH, (g) -HC=NOC-|-3alkyl optionally substituted with 1-3 halogens, (h) -(CH3)C=NOC-| .salkyl optionally substituted with 1-3 halogens (i) -C(=O)OC-| .salkyl optionally substituted with 1-3 halogens, (j) -C(=O)NHR6’, (k) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and C-|.2alkyl optionally substituted with 1-3 F, (I) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and C-|-2alkyl optionally substituted with 1-3 F, (m) Phenyl, (n) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (0) -C^C-Phenyl, and (p) -CH2-Phenyl, wherein the -CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and C-|.2alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi . salkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci .salkyl optionally substituted with 1-3 halogens, (v) -OC-|-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
R4’ and R5’ are each independently selected from the group consisting of:
(a) hydrogen;
36
RECTIFIED SHEET (RULE 91 )
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C-| -3 alkyl, or C1.3 haloalkyl; and
(c) -(CRaRb)i.2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOxCH3,
(viii) -S(C=O)R7and
(ix) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOXCH3, -SO2NH2, C1-3 alkyl, C1-3 haloalkyl, -OC1-3 alkyl, or -OC i-3 haloalkyl; or R4’ and R5 together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl, (iii) -(C=O)OH, (iv) C1 3 alkyl optionally substituted with hydroxy or 1 -3 halogens, (v) -OC1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, or Ci 3 haloalkyl;, and
R6’ js selected from the group consisting of H, C-| -3alkyl optionally substituted with 1 - 3 halogens, Phenyl, and -CH2-Phenyl, wherein Phenyl in both occurrences is optionally substituted with 1 -3 substituents independently selected from (i) halogen, (ii) -C(=O)OC-|-3alkyl optionally
37
RECTIFIED SHEET (RULE 91 )
substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci .galkyl optionally substituted with 1-3 halogens, and (v) -OC-| -3alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of C1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC1 3 alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1 -3 halogens, C1 3 alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2;
[00115] The compound of formula II may be of structural Formula Ila, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
Ila wherein
R1 ’ is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OCi-salkyl optionally substituted with 1-3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -HC=NOH, (e) -(CH3)C=NOH, (f) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (g) -(CH3)C=NOCi-3alkyl optionally substituted with 1 -3 halogens, (h) -C(=O)OCi-3alkyl optionally substituted with 1 -3 halogens, (i) -C(=O)NHR6’, (j) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and C^alkyl optionally substituted with 1-3 F, (k) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1 -4 substituents independently selected from halogen and Ci- 2 alkyl optionally substituted with 1-3 F, (I) Phenyl, (m) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (n) -C=C-Phenyl, (o) -CH2-Phenyl, and (p) -CN, wherein the - CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and C1-2 alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1 -3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi.
38
RECTIFIED SHEET (RULE 91 )
salkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH, (iv) Ci-salkyl optionally substituted with 1 -3 halogens, (v) -OCi.3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R3’ is halogen;
R4 and R5 are each independently selected from the group consisting of:
(a) hydrogen:
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C-| -3 alkyl, or C1-3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOxCH3,
(viii) -S(C=O)R7, and
(xiii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOxCHs, -SO2NH2, C1-3 alkyl, C1-3 haloalkyl, -OC1-3 alkyl, or -OC 1-3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl, (iii) -(C=O)OH, (iv) C1 3 alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -OC1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1 -3 halogens, C1 3 alkyl, or C1-3 haloalkyl;
R6 is selected from the group consisting of H, C1 3 alkyl optionally substituted with 1-3 halogens, phenyl, or -CH2-phenyl, wherein phenyl is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=o c1-3 alkyl optionally substituted with 1 -3
39
RECTIFIED SHEET (RULE 91 )
halogens, (iii) -COOH, (iv) C1 3 alkyl optionally substituted with 1 -3 halogens, and (v) -OC1 3 alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of C1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -OC1 3 alkyl, (iii) aryl, and (iv) heteroaryl, wherein wherein the aryl and heteroaryl are optionally substituted with 1 -3 halogens, C1 3 alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1 -5 fluorines; and x is 0, 1 , or 2.
RECTIFIED SHEET (RULE 91)
[00118] Compounds of structural Formula I, structural Formula la and/or structural Formula lb and/or structural Formula II and/or structural Formula Ila may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of structural Formula I, structural Formula la and/or structural Formula lb.
[00119] Compounds of structural Formula I, structural Formula la, structural Formula lb and/or structural Formula II and/or structural Formula Ila may be separated into their individual diastereoisomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof, or via chiral chromatography using an optically active stationary phase. Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.
[00120] Alternatively, any stereoisomer of a compound of the general structural Formula I, structural Formula la, structural Formula lb and/or structural Formula II and/or structural Formula Ila may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known absolute configuration.
[00121] If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base. The diasteromeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
[00122] Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
[00123] Some of the compounds described herein may exist as tautomers, which have different points of attachment of hydrogen accompanied by one or more double bond shifts. For example, a ketone and its enol form are keto-enol tautomers. The individual tautomers as well as mixtures thereof are encompassed with compounds of the present invention.
[00124] In the compounds of generic Formula I, Formula la, Formula lb, Formula II and/or Formula Ila, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may 42
RECTIFIED SHEET (RULE 91 )
be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I, Formula la, Formula lb and/or structural Formula II and/or structural Formula Ila. For example, different isotopic forms of hydrogen (H) include protium (1H) and deuterium (2H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically- enriched compounds within generic Formula I, Formula la, Formula lb, Formula II and/or Formula Ila can be prepared without undue experimentation by conventional techniqueswell known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
[00125] The term “subject” as used herein, is a human patient or other animal such as another mammal with functional mast cells, basophils, neutrophils, eosinophils, monocytes, macrophages, dendritic cells, and Langerhans cells.
[00126] Before describing the present invention in detail, a numberof terms will be defined. As used herein, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.
[00127] It is noted that terms like “preferably”, “commonly”, and “typically” are not utilized herein to limit the scope of the claimed invention or to imply that certain features are critical, essential, or even important to the structure or function of the claimed invention. Rather, these terms are merely intended to highlight alternative or additional features that can or cannot be utilized in a particular embodiment of the present invention.
[00128] For the purposes of describing and defining the present invention it is noted that the term “substantially” is utilized herein to represent the inherent degree of uncertainty that can be attributed to any quantitative comparison, value, measurement, or other representation. The term “substantially” is also utilized herein to represent the degree by which a quantitative representation can vary from a stated reference without resulting in a change in the basic function of the subject matter at issue.
Salts and formulations
[00129] It will be understood that, as used herein, references to the compounds of structural Formula I, Formula la, Formula lb, Formula II and/or Formula Ila are meant to also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they 43
RECTIFIED SHEET (RULE 91 )
are used as precursors to the free compounds or their pharmaceutically acceptable salts or in other synthetic manipulations. The term "pharmaceutically acceptable salt" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed within the term "pharmaceutically acceptable salt" referto non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts of basic compounds of the present invention include, but are not limited to, the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide and valerate. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N- ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
[00130] Also, in the case of a carboxylic acid (-COOH) or alcohol group being present in the compounds of the present invention, pharmaceutically acceptable esters of carboxylic acid derivatives, such as methyl, ethyl, or pivaloyloxymethyl, or acyl derivatives of alcohols, such as acetyl, pivaloyl, benzoyl, and aminoacyl, can be employed. Included are those esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations.
[00131] Solvates, in particular hydrates, of the compounds of structural Formula I, Formula la, Formula lb, Formula II and/or Formula Ila are included in the present invention as well.
44
RECTIFIED SHEET (RULE 91 )
[00132] The pharmaceutical compositions may be in the form of a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1 ,3- butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Immune checkpoint inhibitors
[00133] The role of immune checkpoints is to prevent an immune response from being so strong that it destroys healthy cells in the body. Immune checkpoints engage when proteins on the surface of T cells recognize and bind to partner proteins on other cells, such as some tumor cells. These proteins are called immune checkpoint proteins. When the checkpoint and partner proteins bind together, they send an “off’ signal to the T cells. This can prevent the immune system from destroying the cancer.
[00134] Immunotherapy drugs called immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the “off’ signal from being sent, allowing the T cells to kill cancer cells. One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called Programmed cell death protein 1 , also known as PD-1 or its partner protein Programmed death-ligand 1 (PD-L1 ). Some tumors turn down the T cell response by producing lots of PD-L1.
[00135] The most recognized checkpoint inhibitors are anti-PD1 and anti-CTLA4, yet in the interaction of dendritic cells with tumors cells, effector T-cells, and other immune cells, a number of protein interactions favoring or inhibiting the recognition and killing of tumor cells has been identified. For example, a dozen of those interactions have been reported to affect DC and tumors cells (K. Palucka and J. Banchereau, Nature Reviews Cancer 12:265-277). Hence the technology described herein may be conjugated to many of those additional immunotherapy technologies currently in development.
[00136] According to embodiment, the immune checkpoint inhibitor may therefore be an anti- PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or molecular inhibitors of these receptors.
[00137] The anti-PD-1 antibody may be selected from the group consisting of nivolumab antibody, pembrolizumab antibody, pidilizumab antibody, cemiplimab antibody, dostarlimab antibody, JTX-4014 antibody, Spartalizumab antibody, Camrelizumab antibody, Sintilimab antibody, 45
RECTIFIED SHEET (RULE 91 )
Tislelizumab antibody, Toripalimab antibody, INCMGA00012 antibody, AMP-224 antibody, AMP-514 antibody, RMP1-14 antibody or combinations thereof.
[00138] The anti-PDL-1 antibody may be selected from the group consisting of B7-H1 antibody, BMS-936559 antibody, MPDL3280A (atezolizumab) antibody, MEDI-4736 antibody, MSB0010718C antibody, 10F-9G2 antibody, avelumab antibody, durvalumab antibody, or combinations thereof.
[00139] The anti-CTLA-4 antibody may be selected from the group consisting of ipilimumab or tremelimumab or combinations thereof.
Utilities
[00140] The compounds specifically exemplified herein exhibit good efficacy in inhibiting the PTPN1/PTP1 B and PTPN2/TCPTP enzymes, as shown by their in vitro assays. The compounds generally have an IC50 value of less than 10 pM in the enzyme assay described in the Assays section, and preferably have an IC50 value of less than 1 pM.
[00141] One aspect of the invention provides a method for the treatment and control of cancer, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula I, Formula la, Formula lb, Formula II and/or compounds of Formula Ila, in combination with an immune checkpoint inhibitor. Combined together, the compound of Formula I, Formula la, Formula lb, Formula II and/or compounds of Formula Ila and the immune checkpoint inhibitor provide an unexpectedly enhanced treatment that may not be obtained from the treatment with either component alone.
[00142] In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent, such as a mouse, can be treated. However, the method can also be practiced in other species, such as avian species (e.g., chickens).
Kits
[00143] Compounds of Formula I, Formula la, Formula lb, Formula II and Formula Ila when being used for treatment purposes, may be packaged for use as a crystalline solid, an amorphous solid or a lyophilized powder. Suitable quantities range from about 0.1 mg to 1 g. Ideally, the compound is packaged in a container to which a suitable solvent can be added to achieve the desired concentration of solution. Alternatively, the compound may be packaged as an aqueous solution at a fixed concentration, or as a solution in a water-soluble organic solvent at a fixed concentration. Suitable 46
RECTIFIED SHEET (RULE 91 )
organic solvents may include DMSO, methanol, ethanol or acetonitrile, or mixtures of these solvents with water. Suitable concentrations are about 0.1 mM to about 25 mM.
[00144] The present invention includes kits encompassing the compounds of Formula I, Formula la, Formula lb, formula II and/or Formula Ila, and instructions on how to use said compounds. According to an embodiment, the kit may also include appropriate immune checkpoint inhibitor. The kit will allow a patient to be conveniently treated. This treatment can be optimized to work best with current clinical therapeutic standards.
[00145] The compound of Formula I, Formula la, Formula lb, Formula II and/or Formula Ila may be administered to a patient in need of immunotherapy in one or more injections. The frequency of injection and the intervals between injections of the compound and/or immune checkpoint inhibitor will be adjusted to maximize the therapeutic response. For example, injections may occur once, twice, or more times daily, once, twice, or more times weekly, biweekly, monthly or bimonthly or at any other intervals deemed most suitable to the therapeutic benefit of the patient. The compound of Formula I, Formula la, Formula lb, Formula II and/or Formula Ila may be administered prior to administration of the immune checkpoint inhibitor.
[00146] The administration of the compound of Formula I, Formula la, Formula lb, Formula II and/or Formula Ila may be an intratumoral administration. The administration of the compound of structural Formula I, Formula la, Formula lb, Formula II and/or Formula Ila may be an oral administration. The administration of the immune checkpoint inhibitor may be a systemic administration, and intratumoral administration, or a combination thereof.
[00147] The administration of said compound of structural Formula I, Formula la, Formula lb, Formula II and/or Formula Ila may be an intratumoral administration and the administration of the immune checkpoint inhibitor may be a systemic administration, an intratumoral administration, or a combination thereof, or the administration of the compound of structural Formula I may be an intratumoral administration and administration of the immune checkpoint inhibitor may be a systemic administration, an intratumoral administration, or a combination thereof, or administration of the compound of structural Formula I may be an oral administration and administration of the immune checkpoint inhibitor may be a systemic administration, an intratumoral administration, ora combination thereof.
Combination Therapy
[00148] A patient in need of immunotherapy may be treated with the compound of Formula I, Formula la, Formula lb, Formula II and/or Formula Ila and the immune checkpoint inhibitor, contemporaneously with other treatments known to the medical practitioner. The use of such multiple 47
RECTIFIED SHEET (RULE 91 )
treatments may be particularly advantageous to the patient. Such treatments may include, but are not limited to, surgical resection, radiation, chemotherapy, targeted therapy and other types of immunotherapy. Chemotherapy agents that may be used include: a) cytotoxic agents such as taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1 -dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof; b) antimetabolites such as methotrexate, 6-mercaptopurine, 6-thioguanine, gemcitabine, cytarabine, 5-fluorouracil decarbazine; c) alkylating agents such as mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin; d) anthracyclines such as daunorubicin and doxorubicin; e) antibiotics such as dactinomycin, bleomycin, mithramycin, and anthramycin (AMC); f) anti-mitotic agents such as vincristine and vinblastine; g) targeted therapies that may be used include, but they are not limited to: hormone therapies (such as degarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist that reduces testosterone levels in prostate cancer), signal transduction inhibitors (such as imatinib, trastuzumab, PARPi, and CDKi), as well as gene expression modulators (for example the HDAC inhibitors panobinostatand belinostat), apoptosis inducers (such as recombinant human TNF-related apoptosis-inducing ligand (TRAIL)) and angiogenesis inhibitors (such as sorafenib, sunitinib, pazopanib and everolimus); h) Immunotherapy agents that may be used include: monoclonal antibodies treatment (anti- LAG3, anti-KIR), and dendritic cell (DC) vaccines.
Monitoring
[00149] According to another embodiment, the methods or uses of the present invention may further comprise monitoring the activity of the compound of structural Formula I, structural Formula II or both structural Formula I and structural Formula II during their respective uses. For example, targeted cells, such as PBMCs can be collected from blood drawn from a patient treated with the compounds of the present invention, and the phosphorylation states of downstream targets of TCPTP
48
RECTIFIED SHEET (RULE 91 )
(PTPN2) and PTP1B (PTPN1 ) may be monitored. As per examples below, the monitoring may take place by immunoblotting, but could also take place through other means of measuring the phosphorylation states of these downstream targets. For example, monitoring could be performed by measuring the fluorescence from a fluorescently labelled antibody specific to any one of the PTPN1/PTPN2 downstream targets, by Fluorescent activated Cell Sorting, mass spectrometry and others.
[00150] The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.
EXAMPLE 1
CONDITIONAL TCPTP AND/OR PTP1 B INACTIVATION IN ENDOGENOUS
CD8+ T CELLS OF MICE
[00151] To address the combined contribution of TCPTP and PTP1 B to the regulation of activating signals in CD8+ T cells, mouse lines where allelic inactivation of either one or both of these genes was specifically induced in mature CD8+ T cells. To achieve this, heterozygous mice carrying “floxed” alleles of both genes, TCPTP [30] and PTP1B [31], were bred with a mouse line where the CRE recombinase expression is driven by the CD8 enhancer 8I (E8i-CRE) [32], Mice were bred to produce littermates with either WT (wt/wt), heterozygous (wt/fl) or homozygous (fl/fl) versions of either single TCPTP or PTP1 B, or both genes. Throughout the experiments, heterozygous E8i-CRE (wt/cre+) expression was maintained to achieve deletion. To avoid accounting potential artifactsarising from off- target effects of the CRE recombinase [33, 34], mice heterozygous for E8i-CRE (wt/cre+) carrying wt alleles for TCPTP and PTP1 B were used as controls, here after named CRE. Mice were born at mendelian rates, and no apparent differences were detected between the various genotypes until 6-8 weeks of age. CD8 T cells from all genotypes reached maturity and distributed in peripheral secondary immune organs (Fig. 1 ). To confirm that conditional deletion of both genes was achieved, protein expression of TC-PTP and PTP1 B was tested by immunoblotting in both peripheral CD4 and CD8 T cells (Fig. 2). As expected, protein expression corresponded to each genotype and was not observed in CD4 T cells. Nevertheless, around 10 weeks of age mice lacking expression of both genes in CD8+ T cells (ptpnl fl/fl; ptpn2 fl/fl; wt/cre+) ordKO hereafter, showed a significant reduction in thymus size with complete involution observed around 12 weeks of age (Fig. 2B). Microscopically the cortical and medullary architecture was loss in thymi of these mice (Fig. 2C) when compared to CRE controls. In the same mice, mild splenomegaly and spontaneous lymphadenopathies were observed. In contrast, other genotypes tested did not show differences in organ size when compared to CRE controls (Fig. 2D).
49
RECTIFIED SHEET (RULE 91 )
EXAMPLE 2
ANALYSIS OF CIRCULATING T CELLS
[00152] Next, circulating CD8 populations from the different genotypes were analyzed by flow cytometric analysis. Although CD8 T cells were present in spleen and lymph nodes of all the genotypes analyzed, mice with dKO CD8 T cells showed an increase in the CD4/CD8 T cell ratio in lymph nodes. However, the absolute number of T cells was not significantly affected (Figs. 1A, 1 B and 2E). This finding, together with the size increase of lymph nodes suggested a change in the migratory cues of lymph nodes. No other significant differences in the distribution of T cells in lymph nodes or spleen was noted. Notwithstanding, subpopulation of CD8 T cells expressing low levels of the CD8 coreceptor were detected in the spleen of mice producing cells with the most extreme genotypes, dKO and TCKO/1BHet (ptpnl wt/fl; Ptpn2 fl/fl; wt/cre+) T cells (Figs. 1A and 1D). The accumulation of these CD8low expressing cells was more pronounced in the dKO animals, almost double the amount seen in the TCKO/1 BHet animals, comprising around 70% and 40% of all splenic CD8 T cells respectively (Figs. 1 C and 1 D). Cells displaying this phenotype were also observed in CRE controls, and both single KO, however they were present at much lesser percentages (ranging from an average 13% to 17%) and differences were not statistically significant (Figs. 1C and 1 D). To further characterize peripheral CD8 T cells in these animals, their differentiation state was assessed by co-staining for the trafficking molecule CD62L and the memory marker CD44 (Fig. 1E). Different CD8 T cell subpopulations of the spleen and peripheral lymph nodes were sorted based on L-selectin (CD62L) and CD44 surface molecule expression defining naive, effector/effector memory and central memory subpopulations (Figs. 1 E and 1 F). While the differentiation state of CD8 T cells in lymph nodes seemed unaffected within the various genotypes, spleens showed a marked increase of effector/effector memory like CD8 T cells in the TCKO/1 BHet mice (ptpnl wt/fl; Ptpn2 fl/fl; wt/cre+) and dKO mice. This subset of CD8+ T cells, characterized by reduced expression of CD62L and intermediate expression of CD44, correlated with the presence CD8low cells (Fig. 1 D). To determine if this correlation was indeed obtained from a distinct differentiation state of the CD8low subpopulation the expression of known CD8 differentiation markers in these cells was compared with the CD8high subpopulation. Besides CD44 and CD62L, the expression of the transcription factor EOMES, the IL-7 receptor CD127 and the terminal differentiation marker KLRG1 were evaluated (Figs. 1 G and 1 H). In general, it was found that CD8low cells from the TCKO/1 BHet and dKO mice, besides a strong effector phenotype given by low CD62L and increased CD44 expression, showed a terminal effector phenotype characterized by loss of CD127, a decrease in EOMES expression and a slight increase in KLRG1 expression. These phenotypical characteristics define this subpopulation as short live effector CD8 cells [35], Hence, in
50
RECTIFIED SHEET (RULE 91 )
these 2 genotypes CD8+ T cells tended to spontaneously differentiate into terminal effector cells with preferential migration to the spleen.
EXAMPLE 3
ANALYSIS OF FUNCTIONAL CAPABILITIES OF CDS T CELLS
[00153] To understand the functional capabilities of the CD8 T cells with combined deficiency ofTCPTP and PTP1 B, the conditional mutant mice of Example 1 were bred with OT-1 transgenic mice. OT-1 mice express a T cell receptor (TCR) with affinity for an epitope of chicken ovalbumin (OVA 257- 64) recognized in context of the MHC Class I. OVA specific activated cytotoxic lymphocytes (CTL) were generated in vitro from purified splenic CD8+ T cells of mice with different genotypes. Day 5 CTL cells were then challenged with the OVA expressing thymoma cell line E.G7 in 5-hour in vitro cytotoxicity assays (Figs. 3A, 3B and 4A). Regarding the single mutant cells, an increase ofthe cytolytic activity of CTL deficient forTCPTP was observed, but not in the cells from mice lacking PTP1B, when compared to similarly treated CRE controls. The enhanced effector activity seen in the TCPTP deficient cells is in line with previous observations [20, 21], Remarkably, a significant increase in the cytolytic activity of CTL from TCKO/1 BHet and dKO genotypes over those with sole TCPTP deficiency was consistently observed. This increase was evident at different effector to target ratios, being almost 2- fold at 5:1 and 10:1 ratios when compared to the TCKO (Figs. 3A and 3B). Effector CD8 T cells also contribute to the immune response by the secretion of cytokines as IFN-y, consequently the presence of this cytokine in the supernatant of target cell stimulated CTLs by ELISA was measured. An increase of the secretion of IFN-y was detected in TCPTP and PTP1 B single deficient cells at low effector to target ratios which was more stepped in the PTPN2 KO cells (Fig. 3C). However, a significant reduction of IFN-y concentration was observed in the supernatants from dKO CTLs, more evident in low effector to target ratios while no significant changes were seen in the TCKO/1 BHet, which were conversely the most efficient at tumor lysis (Fig. 3C). As CD8 differentiation dictates the functional state of these cells, analysis by flow cytometry of the expression of the CD62L and CD44 surface markers on this invitro stimulated CTLs was performed (Fig. 3D). A clear deviation in all the genotypes towards the effector/effector memory population was observed when compared to the CRE controls (Figs. 3D and 3E). For comparison purposes the effector/ effector memory window population was expanded to cover a wide range of CD44 expression, nevertheless the dKO cells tended to lose the expression of this receptor as is shown by comparing MFI values of that axis (Fig. 3E).
51
RECTIFIED SHEET (RULE 91 )
EXAMPLE 4
INHIBITION OF TCPTP AND PTP1B WITH PHARMACOLOGICAL INHIBITORS
[00154] Inhibition of both enzymes resulted in enhanced in vitro functionality of CD8 T cells, an effect with potential benefits to reverse inhibitory cues in tumor microenvironments. Next, small molecule inhibitors targeting specifically TC-PTP and PTP1 B were tested, taking advantage of their similarities in their catalytic domain [36], L598 (from here on called Inh1) is a competitive orthosteric soluble compound that can inhibit both phosphatases with equivalent IC50 [37], Given that the main known substrates of TCPTP and PTP1 B are transcription factors or signaling components lying close upstream, the functional changes observed in genetic deficient were assumed to require modulation of gene expression. Hence, OT-1 CTLs were generated in vitro in presence of various concentrations (2, 5 and 10 pM) of Inh, 1 and they were tested at day 5 in cytotoxic assays against E.G7 targets (Figs. 5A and 5B). Treatment with the compound significantly increased the cytotoxic activity of CTLs against E.G7 targets at all concentrations (Figs. 5A and 5B). The cytotoxic activity was highest at 5pM, and no significant differences between 5pM and 10pM was observed, uncovering a limited effect for the inhibitor. As cytokine secretion seems to be also affected by the reduced activity of TC-PTP and PTP1 B IFN-y secretion was quantified in the supernatant of these experiments by ELISA (Fig. 5C). As observed in genetic deficient cells, IFN-y secretion was higher in the lower effector to target ratios, suggesting that low levels of stimulation favor proinflammatory cytokine secretion. In addition, presence of the inhibitor at low concentration (2 pM) correlated with a more significant increase in the secretion of IFN-y, resembling observations in the single TC-PTP or PTP1 B deficient cells. Additionally, increasing the concentration of the inhibitor led to an opposite effect on IFN-y secretion, similarly to that observed in the TCKO/1 BHet or the dKO derived CTLs.
[00155] As the differentiation state of CD8 T cells was altered in the various genotypes analyzed before, how treatment with Inh1 altered the expression of differentiation markers was determined by flow cytometric analysis (Figs. 5D and 5E). Expression of CD62L and CD44 drifted towards a gradual increase of the Tern population (CD62L high, CD44 high events) which correlated to the inhibitor concentration used (Fig. 5E), a marker associated with effector differentiation, correlated to the inhibitor concentration used. The observations showed that treatment with Inh 1 reproduced the phenotypic consequences of combined TC-PTP and PTP1B deficiency in CD8 T cells. To test if the phenotype observed after treatment with I nh1 is a consequence of specific inhibition of TCPTP and PTP1B, CD8 T cell of the different the genotypes used previously were treated with 5 pM Inh1 during in vitro CTL differentiation and tested for specific cytotoxicity against E.G7 cells (Fig. 3F). As seen in WT OT-1 CTLs, CRE controls increased their capacity to lyse E.G7 target cells about 2-fold. In the case of PTP1B single deficient cells, cytotoxicity followed a pattern without significant differences to 52
RECTIFIED SHEET (RULE 91 )
CRE controls, either when treated or not with the inhibitor. Remarkably, PTP1 B deficient CTLs treated with the inhibitor increased their cytolytic capacity to that of TCPTP single deficient cells. These results suggest a requirement for primary TCPTP inhibition for the enhanced activity observed in CD8 cells, and the ability of the inhibitor to target TCPTP activity intracellularly. However, after treatment with the inhibitor, TCPTP single deficient cells still increased their cytolytic activity twice as much when compared to non-treated cells. This increase resembles the increase observed when comparing the TCPTP KO with TCKO/1BHet CTLs. Hence, PTP1 B is targeted intracellularly by the inhibitor and the pharmacological inhibition with 5 pM Inh1 has a comparable effect to the observations in the PTP1B hemizygous cells. Remarkably, the inhibitor did not have an effect on eitherTCKO/1 BHet ordKO CTLs cytotoxic capacities, suggesting that in both of these genotypes, cells are brought to their maximum effector capabilities (Fig. 5F). Next, IFN-y was measured in the cell supernatant of these experiments. As observed previously, cells stimulated at 5 to 1 effector to target ratio in either genetically deficient in TCPTP or those treated with the inhibitor had the highest IFN-y secretion (Fig. 5G). In general, as seen in the previous experiments, reduced activity of TCPTP and PTP1 B led to a decrease in the secretion of IFN-y.
EXAMPLE 5
INHIBITION OF TCPTP AND PTP1B WITH PHARMACOLOGICAL INHIBITORS
[00156] Next, the capacity of Inh 1 to modify the functionality of human T cells was teste. To do so, T cells were enriched from healthy donors PBMCs and stimulated in vitro with anti-CD3 and anti CD28 for 7 days in the presence of increasing amounts of Inh 1. At day 7 the cells were harvested and analyzed by surface and intracellular flow cytometry forthe proinflammatory cytokines IFN-y and TNF- a, and forthe differentiation markers CD45RO and CD62L defining effector and memory populations. In vitro treatment of human T cells with Inh 1 led to an increase in the production and accumulation of both IFN-y and TNF-a in both CD4 and CD8 T cells (Figs. 6A, 6B, 7A and 7B). In all cases the increase seemed to reach its maximum with 2 pM treatment and be maintained at similar extent when treated with increased concentrations. Increase in cytokine production was around 30 to 40% for TNF-a and 50 to 70% for IFN-y, in both CD4 and CD8 T cells. Besides increased proinflammatory cytokine production, also it was also observed that treatment with I n h 1 skewed T cell differentiation towards a central memory phenotype (CD45RO high, CD62L high) in both CD4 and CD8 T cells (Fig. 6C). This increase was more pronounced in CD8 T cells and seemed to correlate to the concentration of inh1 used. We did not find any preference on improving CD4 or CD8 T cells proliferation as both cell types were similarly represented at the different concentrations used of I nh 1 (Fig. 7C).
53
RECTIFIED SHEET (RULE 91 )
EXAMPLE 6
BULK MRNA SEQUENCING
[00157] TCPTP and PTP1B activity regulate several pathways that control transcriptional activity. To understand the changes in gene expression that led to an increase in the effector qualities of CD8 T cells with decreased activity of TCPTP and PTP1 B bulk mRNA sequencing of CTL derived from the different genotypes as well as from cells treated with Inh 1 was performed. The aim was to identify the differentially regulated transcripts by comparative RNAseq (Figs. 8 and 9). To eliminate bias given by the changes in peripheral CD8 differentiation observed in vivo, we generated CTLs were generated from purified naive splenic CD8 T cells. The most significantly differentially expressed genes were observed when comparing 1 BKO and dKO samples to CRE controls (Fig. 9A). The interest was centered on differences between the TCPTP KO cells and the PTP1 B Het/TCPTP KO cells, to determine the genes implicated in the enhanced effector properties. A heatmap built on the differential expression between TCKO/1 BHet and CRE controls showed a clear resemblance with the genetic footprint of the single TCKO (Fig. 8A). However, the single 1 BKO footprint distributed similarly to that of CRE controls, highlighting firstly divergent regulatory functions between both genes, and secondly the role of TCPTP in controlling genes related to immune response. Still, some downregulated and upregulated transcripts coincided between the 1 BKO samples and the TCKO/1 BHet. At the same time, their expression levels were different than thatofthe TCKO implying that some PTP1 B regulated genes contribute to the phenotype of the TCKO/1 BHet cells (Fig. 8A). To highlight these differences, the transcriptomes of TCKO/1 BHet cells were directly compared to the TCKO cells (Fig. 8B). 376 differentially expressed genes were identified (Table 1 presents genes showing ± 0.5 Iog2 fold change). This list of differentially expressed genes shows a transcriptome that leans towards an effector T cell phenotype, characterized by positively regulated effector genes such as Prf1 , and Gzmb, potentially as consequence of the down regulation of the transcription factors Tcf7 and EOMES [38], and down regulation of the naTve/memory marker Sell (CD62L). It was also noticed that the triggering of counter-modulatory mechanisms, as the inhibitory receptor klrkl, the Jak/STAT regulator ASB2 and the cytokines IL-10, Tgfb3 and cytokine receptor for IL-13, IL-13ra1 , were upregulated, potentially by the presence of the transcription factor Maf, which was also found increased. Given the large amount of data generated, a biased approach was used to highlight the transcriptomic signature ofthe different genotypes analyzed based on known CD8 T cell functionally relevant genes.A comparative signature between CTL differentiated in vitro from C57BL/6 naive spleen CD8 T cells treated or not with 5 M Inh1 (Figure 5C) was added to this analysis. As the results presented above suggest, TCPTP deficiency corresponds to an increase in effector molecule expression (e.g., granzymes and perforin), reduction of migratory receptors to secondary immune organs (e.g., CD62L and CCR7), mild
54
RECTIFIED SHEET (RULE 91 )
expression of inhibitory receptors (e.g., PD1 , Tigit and Tim-3), and increased expression of chemokines CCL3, 4 and 5. Surprisingly, deletion of PTP1B potentiated this effector phenotype in the TCPTP deficient background, an effect that correlated to the number of alleles deleted, been more evident in the dKO than in the TCKO/1 BHet cells. In contrast, there was a large discrepancy for the transcriptomic signature of the PTP1 B deficient cells when compared to all othercells analyzed. 1 BKO cells transcriptome resembled that of memory T cells, characterized by the upregulation of the IL-7 receptor CD127, CD62L, CXCR5 and CD28, and upregulation of the transcription factor Tcf1. These cells also showed characteristics of exhausted T cells like high expression of the inhibitory receptors Tigit, SLAMF6, CD38 and CTLA4. Similarly, although the transcriptome of dKO cells correlated to that of single TCPTP KO cells, these dKO cells also expressed higher levels of receptors associated with exhaustion, as Tim-3, Tigit, Lag3, Entpdl and PD-1. Even more, ectopic expression of the Th17 related transcription factor Rorc in dKO suggests dysregulation of differentiation, a phenomenon observed in CD4 Treg cells [39], Supporting even further the dysfunctional state of dKO cells, upregulation of the three members of the transcription factor family NR4A (Fig. 9C) associated with establishment of exhaustion in CD8 T cells was detected [40], These observations are in line with the phenotypical and functional analyses discussed above, supporting the idea that complete inhibition of both of the TCPTP and PTP1 B enzymes leads to important developmental dysregulation. Correspondingly, the transcriptome of CD8 T cells treated with Inh1 highly resembles that of the TCKO and TCKO/1 BHet and confirming that the mechanisms improving the effector qualities of T cells treated with Inh1 are similar to the changes observed in the genetically deficient T cells. IL-10 is one of the highly upregulated mRNA species in the TCKO, TCKO/1 BHet, dKO and the T cells treated with the inh1. T radition ally considered as a regulatory cytokine, IL-10 has been more recently associated to improved antitumoral responses and prevention of CD8 T cell exhaustion. The presence of IL-10 in the supernatants of in vitro cytotoxicity assays was tested by ELISA (Fig. 9D). IL-10 secretion in these conditions followed an almost identical pattern to the findings in cytotoxicity discussed above. PTP1B single deficient T cells were no different than CRE controls. In contrast TCKO, TCKO/1 BHet and dKO cells showed a gradual increment of IL-10 secretion in their corresponding supernatants. Furthermore, additional treatment with 5 M Inh1 resulted in an almost global increase in IL-10 secretion on the conditions tested except for the T cells derived from dKO mice, which were insensitive to the presence of Inh 1 . As an alternative readout to cytotoxicity experiments, secretion of IL-10 confirmed the effects of gradual inhibition of these enzymes and the specificity of the inhibitor.
55
RECTIFIED SHEET (RULE 91 )
Table 1 - Differentially expressed genes showing ± 0.5 Iog2 fold change
EXAMPLE 7
CYTOTOXIC T LYMPHOCYTE STIMULATION WITH INF-y
[00158] Previous reports on TCPTP deficient CD8 T cells identified dysregulation of Type I interferon signals as the main source for phenotypical changes. However, in the present analysis a strong dysregulation of interferon regulated genes was not observed in samples from the TCKO, TCKO/1BHet ordKO T cells. Indeed, upregulation of such mRNAs was only observed in samples from the 1 BKO animals. Type I interferon signals are transduced by members of the JAK and STAT families, 56
RECTIFIED SHEET (RULE 91 )
which are well known targets of TCPTP and PTP1 B. To investigate how the combined absence of these phosphatases modify Type I interferon signals, CTL carrying different genotypes were stimulated with IFN-y for 10 and 30 minutes and the levels phosphorylation were analyzed on the canonical dimerizing c-terminal phosphotyrosine residues by immunoblotting with specific antibodies. CRE control cells responded to IFN-y by increasing phosphorylation of these residues in STATs 1 , 2, 3, 4 and 5a (Fig. 10A, 10B and 10C) revealing the complexity of type I interferon signals in CD8 cells. No increase in the phosphorylation of STAT6 was observed either in CRE control cells or in any of the genotypes analyzed. Deficiency of either of these phosphatases resulted in the increased phosphorylation of STATS 1 , 3 and 5, while phosphorylation levels of STAT4 seemed unaffected. A similar response pattern was observed in cells from TCKO/1 BHet, confirming that these cells are more sensitive to stimulation with type I interferons. Conversely, dKO cells were highly hyporesponsive with decreased phosphorylation of STATS 1 , 3 and 5, and although the ratio of phosphorylated STAT4 to total protein was conserved, a clear restriction in protein expression in these cells resulted in low availability of the phosphorylated version. dKO cells were largely different to controls at basal level as well, where protein expression and levels of phosphorylation were also affected. Particularly, and in opposition to STAT4, increased expression of STATs 1 and 3 was detected, accompanied with increased basal level phosphorylation of STAT3. Higher expression and basal phosphorylation of STAT3 was also seen in TCKO and TCKO/1 BHet samples, potentially related to the global changes in transcription seen in these cells.
EXAMPLE 8
KNOCK DOWN OF TRANSCRIPTION FACTOR BATF3
[00159] One of the potential downstream mechanism by which TCPTP/PTP1 B deficiency takes effect is the upregulation of transcription factor BatF3. BatF3 is linked to the differentiation of CD8+ dendritic cells into a phenotype with enhanced capacities to activate CD8+ T cells, named conventional DC type I (cDC1 ). To test a possible link between BatF3 and the enhanced CD8+ cytotoxicity as a potential master transcription factor driving the enhanced effector properties of TCKO/1 BHet cells, the expression of was knocked down the expression of BatF3 using an siRNA during the in vitro differentiation of TCKO/1 BHet CTLs under the OT-1 background. Using the EG.7 cytotoxicity assay as readout, the functional effector properties of TCKO/1 BHet cells with reduced expression of BatF3 were compared (Fig. 11 A). No appreciable differences in their cytotoxic ability were observed against E.G7 cells when compared to controls transfected with a non-targeting siRNA, despite a clear reduction of BatF3 expression (Fig. 11 B). Even though BatF3 was the most significantly upregulated transcription factor observed in the analysis, the expression of transcripts of other transcription factors know to positively drive CD8 effector differentiation were also increased in those genotypes showing an 57
RECTIFIED SHEET (RULE 91 )
enhanced effector genotype (Fig. 11 C). Immunoblotting confirmed an elevation of protein products for IRF4, Myb, ZEB and BLIMP1 , suggesting that transcriptomic changes observed between the different genotypes has a multifactorial origin.
EXAMPLE 9
IN VIVO TREATMENT WITH INHIBITOR 1
[00160] TCPTP and PTP1B have been associated with the control of proinflammatory signals not only in T cells, but also in other immune and non-immune cells. Indeed, it has been proposed that decreased activity of these phosphatases may be beneficial to antitumoral responses. To test the antitumoral activity of Inh1 in vivo, the compound was injected in WT C57BL/6 mice bearing E.G7 thymoma. TCPTP and PTP1 B are ubiquitous enzymes with a broad range of activities involving several cytokine and growth factor receptor signals transduction. To avoid systemic side effects resulting from the use of Inh1, the compound was injected intratumorally, limiting its activity to the tumor microenvironment. To do so, E.G7 thymoma tumors were injected in WT C57BL/6 mice and their growth was monitored by caliper measurement. Tumors were injected with In hi from day 10 every 48 hours with an equivalent of 50 pM of the compound or with PBS (Fig. 12A). As expected, in PBS injected controls, tumor growth proceeded exponentially. Conversely, tumors injected with Inh1 maintained a similar size during the extent of the observations. Treatment with Inh1 clearly and unexpectedly limited tumor growth, potentially through cells intrinsic and immune mechanisms.
EXAMPLE 10
COMBINED IN VIVO TREATMENT WITH INHIBITOR 2 AND ANTI PD-1 THERAPY
[00161] As EG.7 cells are engineered to express the exogenous antigen OVA, they can artificially contribute to the capacity of Inh1 to induce a targeting immune response. To avoid such potential artifact, the syngeneic melanoma model B16F10 was used in the C57BL/6 background. The syngeneic melanoma model B16F10 is a tumor model known to be poorly immunogenic. In these experiments, an alternative molecule from the same series of compounds as Inh1 , here in called Inhibitor 2 (Inh2), was used. I nh2 is disclosed in W02008089581 and the following formula:
[00162] This compound has been used in phase 1 clinical studies, and it is known to be tolerated systemically in mice and humans. Inh2 has more potent inhibitory capacity, with an IC50 in vitro up to 3 times higher for both enzymes (Fig. 12B) which was reflected in its capacity to induce 58
RECTIFIED SHEET (RULE 91 )
similar biological activity to Inh1 at concentrations 5 times lower (Fig. 12C). B16F10 melanoma is a “cold tumor” cancer model used to demonstrate the immunogenetic properties of immune checkpoint blockade therapies, including those based in anti-PD-1 antibodies with important clinical success. To test the capacity of TCPTP and PTP1 B inhibition combined with immune checkpoint blockade therapies, to limit B16F10 tumors growth, the compound and an anti-PD-1 monoclonal antibody were injected intratumorally as described above. The anti-PD-1 antibody used is the RMP1-14 monoclonal antibody which reacts with mouse PD-1 (also known as CD279) from BioXCell, Cat. No. BP0146. It is a rat lgG2a, K. NOW referring to Fig. 13. Although treatment with the I n h2 alone slowed tumoral growth, its effect was not significant (Figs. 13A and B). Conversely, single treatment with anti-PD-1 showed a significant reduction of tumor growth and prolonged survival, as reported before. Unexpectedly, the combined use of anti-PD1 and I nh2 significantly further reduced the development of the B16F10 tumor when compared to anti-PD-1 therapy alone. Furthermore, combined therapy resulted in 100% subject survival at day 25 post injection.
EXAMPLE 11
DISCUSSION
[00163] The present application shows the combined influence of the phosphatases PTP1B and TCPTP in CD8 T cell function, and their potential as immunotherapeutic targets. Herein, the effects of reduced expression of both genes in CD8T cells was studied. Double deleted mutant cells displayed a heavily modified phenotype resembling terminally differentiated effector T cells. These T cells made up to 80% of peripheral CD8 T cells in young unchallenged mice, suggesting that they were spontaneously activated, since control CRE expressing animals displayed only about 10% terminally differentiated effector T cells. Functional analysis supports the phenotypical findings as these T cells were highly cytotoxic against antigen specific target cells. Deeper study of their differentiation state at protein and mRNA level placed dKO cells as terminal exhausted cells with high expression of Tim-3, TIGIT, LAG-3, CD244a, PD1 and Entpdl . These cells also highly expressed all the members of the NR4A family of transcription factors, known to mediated CD8 exhaustion [40] and showed altered STAT transcription factors expression.
[00164] Regarding the single deficiency of TCPTP in CD8 T cells, the results above show that it confers better effector T cell qualities against tumors while providing protection from T cell exhaustion [20, 21], Surprisingly, when TCPTO deficiency is accompanied by partial deletion of PTP1 B, e.g., in TCKO/1BHet T cells, the phenotype of TCPTP deficient cells was potentiated with an even greater increased in the cytolytic ability on antigen specific target cells. Nevertheless, these TCKO/1 BHet T cells did not show the extreme phenotypical or transcriptional changes observed in the double deficient
59
RECTIFIED SHEET (RULE 91 )
T cells. Single PTP1 B deficient CD8 T cells were highly divergent from TCPTP deficient cells. Surprisingly, the transcriptomic signature of TCKO/1 BHet and dKO T cells nevertheless resembled accurately that of the TCPTP single deficient cells. PTP1 B single deficient T cells phenotypically did not resemble effector CD8 T cells, nor did they show improved functional effector qualities over CRE expressing controls. These findings are contrating with those from others [22]. One potential caveat in Wiede’s et al study [22] is the use of CRE negative controls, leaving unaccounted potential nonspecific consequences of CRE expression [33, 34],
[00165] A direct correlation of the cytotoxic capacity of CD8 T cells to the degree of functional silencing of TCPTP and PTP1 B was observed, either genetically or pharmacologically, corresponding to the differentiation stage. However, secretion of IFN-y did not follow such correlation. Instead, a peak production with mild inhibition was observed, dictated either by low or intermediate concentrations of inh1 or by deleting each phosphatase gene individually. However, at higher levels of inhibition (either uncombined orfrom combined genetic/pharmacological inhibition) production of IFN-y decreased. This discrepancy between readouts of effector function is interpreted as resulting from control by independent feedback mechanisms, the understanding of which will broaden the range for future therapeutic intervention. Conversely, as predicted but mRNA analysis, IL-10 secretion correlated with the cytotoxic capacity of the T cells and with the level of inhibition of TCPTP / PTP1 B. IL-10 is classically regarded as an immunosuppressive cytokine, however recent literature highlights a role for this cytokine in reprograming metabolically exhausted CD8 T cells favoring antitumor responses [1], a potential mechanism involved in the enhanced antitumoral effects of TCPTP / PTP1 B inhibitors. Autocrine stimulation by the secreted IL-10 can also explain the increase of phosphorylated STAT3 seen after type I IFN stimulation of TCPTP / PTP1 B deficient cells, further reinforced by elevated expression of STAT3. The secretion pattern of IL-10 in the different cells analyzed suggests a commanding regulatory role for TCPTP in T cells as its deletion was required to observe an effect from PTP1 B inhibition/deletion. This opposes previous findings in macrophages [42], where PTP1 B deficiency alone caused increase of IL-10 production. The proinflammatory phenotype observed in TCPTP deficient cells has been explained by its regulatory role on IFN pathways, more specifically for its roles as a nuclear and cytoplasmic phosphatase for JAK1 and STAT1 [6, 19, 25], However, the data presented herein does not support dysregulation of IFN signals as a potential mechanism given that TCPTP I PTP1 B deficient cells experienced a reduction rather than increase of interferon response related genes.
[00166] Finally, the presented data offers a mechanistic insight on the advantages of developing dual TCPTP / PTP1 B specific inhibitors in immunotherapeutic settings. The high homology between both catalytic domains provides a foundation to prevent of off-target consequences. Given its
60
RECTIFIED SHEET (RULE 91 )
transductional independence from other T cell checkpoint pathways, combinatorial use of TCPTP / PTP1B inhibitors with already immune checkpoint inhibition therapies is an unexpected and surprising new therapeutic avenue. Indeed, synergy of TCPTP / PTP1 B inhibitors with an anti-PD-1 blockade model is shown herein. Furthermore, TCPTP / PTP1 B inhibition does not have to be T cells specific as effects in tumoral [19] and other immune components, as dendritic cells [7], promotes further antitumoral activity.
EXAMPLE 12
STAT PHOSPHORYLATION IN PBMC OF C57BL/6 MICE AFTER 2
HOURS OF INTRAPERITONEAL INJECTION OF INH2
[00167] Protein lysates from PBMC extracted from mice treated with 25mg/kg, 50mg/kg, 100mg/kg and 200mg/kg of I nh2. Samples were migrated in 10% SDS-PAGE gels followed by transfer to PVDF membranes and immunoblot. 10 pg/lane of protein sample loaded. Blot A: anti-Phospho- STAT1 (top), stripped and re-blotted with anti-STAT1 (bottom). Blot B: anti-Phospho -STAT3, stripped and re-blotted with anti-STAT3.
[00168] These results demonstrate the capacity of Inh2 to increase the signaling of JAK/STAT pathway, specifically the tyrosine phosphorylation of STAT1 and STAT3 proteins, in blood immune cells of mice aftersystemic injection. These results provide evidence supporting the effects of the drugs of the present invention on the expected cellular targets and provide supporting evidence fora method to monitor on the activity of the compound in patients and adjust dosage as may be necessary during treatment. In the present example, monitoring is performed with immunoblotting, but other means of monitoring such as fluorescence analysis with fluorescence activated cell sorting or like methods could be envisioned.
61
RECTIFIED SHEET (RULE 91 )
References
1 . Hashimoto, M., et al., CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annual Review of Medicine, 2018. 69(1): p. 301-318.
2. Pike, K.A. and M.L. Tremblay, TC-PTP and PTP1 B: Regulating JAK-STAT signaling, controlling lymphoid malignancies. Cytokine, 2016. 82: p. 52-7.
3. You-Ten, K.E., et al., Impaired Bone Marrow Microenvironment and Immune Function in T Cell Protein Tyrosine Phosphatase-deficient Mice. Journal of Experimental Medicine, 1997. 186(5): p. 683-693.
4. Heinonen, K.M., et al., T-cell protein tyrosine phosphatase deletion results in progressive systemic inflammatory disease. Blood, 2004. 103(9): p. 3457-3464.
5. Miller, B.C., et al., Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nature Immunology, 2019. 20(3): p. 326-336.
6. Heinonen, K.M., et al., Protein tyrosine phosphatases PTP-1 B and TC-PTP play nonredundant roles in macrophage development and IFN-y signaling. Proceedings of the National Academy of Sciences, 2009. 106(23): p. 9368-9372.
7. Penafuerte, C., et al., Down regulation of PTP1 B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNy signaling. Oncolmmunology, 2017. 6(6): p. e1321185.
8. Galon, J., et al., Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science, 2006. 313(5795): p. 1960-1964.
9. Kmiecik, J., et al., Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. Journal of Neuroimmunology, 2013. 264(1): p. 71-83.
10. Djenidi, F., et al., CD8<sup>+</sup>CD103<sup>+</sup> Tumor-Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients. The Journal of Immunology, 2015. 194(7): p. 3475-3486.
1 1. Dudley, M.E., et al., Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. Science, 2002. 298(5594): p. 850-854.
12. Berger, C., et al., Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. The Journal of Clinical Investigation, 2008. 118(1): p. 294- 305.
13. Rosenberg, S.A., et al., Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research, 2011 . 17(13): p. 4550-4557.
14. Haslam, A., J. Gill, and V. Prasad, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Network Open, 2020. 3(3): p. e200423-e200423.
15. Waldman, A.D., J.M. Fritz, and M.J. Lenardo, A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology, 2020. 20(11): p. 651-668.
16. Townsend, E.C., et al., The Public Repository of Xenografts Enables Discovery and Randomized Phase Il-like Trials in Mice. Cancer Cell. 29(4): p. 574-586.
17. Penafuerte, C., et al., Mining the Complex Family of Protein Tyrosine Phosphatases for Checkpoint Regulators in Immunity. 2017, Springer Berlin Heidelberg: Berlin, Heidelberg, p. 1-24.
18. Simoncic, P.D., C.J. McGIade, and M.L. Tremblay, PTP1 B and TC-PTP: novel roles in immune-cell signalingThis paper is one of a selection of papers published in this Special issue, entitled Second Messengers and Phosphoproteins — 12th International Conference. Canadian Journal of Physiology and Pharmacology, 2006. 84(7): p. 667-675.
19. Manguso, R.T., et al., In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature, 2017. 547: p. 413.
20. LaFleur, M.W., et al., PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nature Immunology, 2019. 20(10): p. 1335-1347.
21. Wiede, F., et al., PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours. The EMBO Journal, 2019. n/a(n/a): p. e103637.
22. Wiede, F., et al., PTP1 B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. Cancer Discovery, 2022. 12(3): p. 752-773.
23. Myers, M.P., et al., TYK2 andJAK2 Are Substrates of Protein-tyrosine Phosphatase 1B. Journal of Biological Chemistry, 2001 . 276(51): p. 47771-47774.
24. Lu, X., et al., PTP1 B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood, 2008. 112(10): p. 4098-4108.
25. Simoncic, P.D., et al., The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol, 2002. 12(6): p. 446-53.
26. Bourdeau, A., et al., Inhibition of T Cell Protein Tyrosine Phosphatase Enhances lnterleukin-18- Dependent Hematopoietic Stem Cell Expansion. STEM CELLS, 2013. 31 (2): p. 293-304.
27. Doody, K.M., A. Bourdeau, and M.L. Tremblay, T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model and implications in human disease. Immunological Reviews, 2009. 228(1): p. 325-341 .
28. Bourdeau, A., et al., TC-PTP-deficient bone marrow stromal cells fail to support normal B lymphopoiesis due to abnormal secretion of interferon-{gamma}. Blood, 2007. 109(10): p. 4220-8.
29. Klaman, L.D., et al., Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1 B-Deficient Mice. Molecular and Cellular Biology, 2000. 20(15): p. 5479-5489.
30. Bussieres-Marmen, S., et al., Loss of T-cell protein tyrosine phosphatase in the intestinal epithelium promotes local inflammation by increasing colonic stem cell proliferation. Cellular & Molecular Immunology, 2018. 15(4): p. 367-376.
31. Zee, T., et al., T-Cell Protein Tyrosine Phosphatase Regulates Bone Resorption and Whole-Body Insulin Sensitivity through Its Expression in Osteoblasts. Molecular and Cellular Biology, 2012. 32(6): p. 1080-1088.
32. Maekawa, Y., et al., Notch2 integrates signaling by the transcription factors RBP-J and CREB1 to promote T cell cytotoxicity. Nature Immunology, 2008. 9: p. 1140.
33. Pepin, G., et al., Cre-dependent DNA recombination activates a STING-dependent innate immune response. Nucleic Acids Research, 2016. 44(11): p. 5356-5364.
34. Carow, B., et al., <em>lck</em>-Driven Cre Expression Alters T Cell Development in the Thymus and the Frequencies and Functions of Peripheral T Cell Subsets. The Journal of Immunology, 2016: p. 1600827.
35. Herndler-Brandstetter, D., et al., KLRG1 + Effector CD8+ T Cells Lose KLRG1 , Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity. Immunity, 2018. 48(4): p. 716-729. e8.
36. Vidovic, D. and S.C. Schurer, Knowledge-Based Characterization of Similarity Relationships in the Human Protein-Tyrosine Phosphatase Family for Rational Inhibitor Design. Journal of Medicinal Chemistry, 2009. 52(21): p. 6649-6659.
37. Montalibet, J., et al., Residues Distant from the Active Site Influence Protein-tyrosine Phosphatase 1 B Inhibitor Binding. Journal of Biological Chemistry, 2006. 281 (8): p. 5258-5266.
38. Danilo, M., et al., Suppression of Tcf1 by Inflammatory Cytokines Facilitates Effector CD8 T Cell Differentiation. Cell Reports, 2018. 22(8): p. 2107-2117.
39. Spalinger, M.R., et al., PTPN2 controls differentiation of CD4+ T cells and limits intestinal inflammation and intestinal dysbiosis. Mucosal Immunol, 2015. 8(4): p. 918-929.
40. Chen, J., et al., NR4A transcription factors limit CAR T cell function in solid tumours. Nature, 2019. 567(7749): p. 530-534.
41. Guo, Y., et al., Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nature Immunology, 2021. 22(6): p. 746-756.
42. Pike, K.A., et al., Protein Tyrosine Phosphatase 1 B Is a Regulator of the lnterleukin-10-lnduced Transcriptional Program in Macrophages. Science Signaling, 2014. 7(324): p. ra43-ra43.
[00170] While preferred embodiments have been described above and illustrated in the accompanying drawings, it will be evident to those skilled in the art that modifications may be made without departing from this disclosure. Such modifications are considered as possible variants comprised in the scope of the disclosure.
Claims
1 . A method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amountof a compound of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof:
Formula II wherein X’ is selected from CH and N;
R1’ is selected from the group consisting of (a) Ci^alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OC salkyl optionally substituted with 1- 3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -CN, (e) -HC=NOH, (f) -(CH3)C=NOH, (g) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens (i) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (j) -C(=O)NHR6’, (k) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, (I) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and Ci -2alkyl optionally substituted with 1-3 F, (m) Phenyl, (n) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (0) -C^C-Phenyl, and (p) -CH2-Phenyl, wherein the -CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci -3alkyl optionally substituted with 1-3 halogens, (v) -OCi-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
R4’ and R5’ are each independently selected from the group consisting of:
(a) hydrogen;
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C-|-3 alkyl, or C1-3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7and
(ix) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOxCHs, -SO2NH2, C1-3 alkyl, C1-3 haloalkyl, -OC1-3 alkyl, or -OC 1-3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(0=0)00^ alkyl, (iii) -(C=O)OH,
alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, or Ci-3 haloalkyl;, and
R6’ is selected from the group consisting of H, Ci-3alkyl optionally substituted with 1-3 halogens, Phenyl, and -CH2-Phenyl, wherein Phenyl in both occurrences is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=0)0Ci-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci -3alkyl optionally substituted with 1-3 halogens, and (v) -OCi- 3alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -0C1 3 alkyl, (iv) aryl, and (v) heteroaryl,
wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C^ alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2; in combination with an immune checkpoint inhibitor.
2. A method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structural Formula I, or pharmaceutically acceptable salts thereof, and stereoisomers thereof:
Formula I wherein:
X is selected from CH and N;
R1 is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, -SO.C.^ alkyl, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; (f) -(C=O)NR5R6; and (g) aryl or heteroaryl wherein the aryl and heteroaryl group itself may be optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C^jOC^ alkyl optionally substituted with 1-3 halogens, (iii) -COOH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -OC1 3 alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, (vii) -CN, and (viii) -SO2NH2;
R2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
R4 is selected from the group consisting of (a) H; (b) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1- 3 halogens, -SOXC1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C^ alkyl or C^ haloalkyl;
R5 and R6 are independently selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally
substituted with 1-3 halogens, -SOXC1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C^ alkyl or C^ haloalkyl;
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with 1-3 groups independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl, (iii) -(C=O)OH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -OC1.3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, (vii) C1 3 hydroxyalkyl, (viii) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C 3 alkyl or C1 3 haloalkyl; and x is an integer from 0 to 2; in combination with an immune checkpoint inhibitor.
3. A method for the treatment of cancer comprising administering to a subject in need thereof a therapeutically effective amount of a combination of a compound of structural Formula I and of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof:
Formula I wherein:
X is selected from CH and N;
R1 is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, -SO.C.^ alkyl, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; (f) -(C=O)NR5R6; and (g) aryl or heteroaryl wherein the aryl and heteroaryl group itself may be optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl optionally substituted with 1-3 halogens, (iii) -COOH (iv) C1-3 alkyl optionally substituted with 1-3 halogens, (v) -OC1-3 alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, (vii) -CN, and (viii) -SO2NH2;
R2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
R4 is selected from the group consisting of (a) H; (b) C1.3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-
3 halogens, -SOXC1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens,
alkyl or C1.3 aloalkyl;
R5 and R6 are independently selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC^ alkyl optionally substituted with 1-3 halogens, -SOXC1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C1 3 alkyl or C1 3 haloalkyl;
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with 1-3 groups independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl, (iii) -(C=O)OH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -OC1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, (vii) C1 3 hydroxyalkyl, (viii) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C
haloalkyl; and x is an integer from 0 to 2;
Formula II wherein X’ is selected from CH and N;
R1’ is selected from the group consisting of (a) Ci-3alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OCi-3alkyl optionally substituted with 1- 3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -CN, (e) -HC=NOH, (f) -(CH3)C=NOH, (g) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens (i) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (j) -C(=O)NHR6’, (k) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and Ci^alkyl optionally substituted with 1-3 F, (I) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and C 1 -2alkyl optionally substituted with 1-3 F, (m) Phenyl, (n) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (0) -C=C-Phenyl, and (p) -CH2-Phenyl, wherein the -CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected
from halogen and Ci-2alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen,
(ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci .galkyl optionally substituted with 1-3 halogens, (v) -OCi-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
R4’ and R5’ are each independently selected from the group consisting of:
(a) hydrogen;
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or C1.3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7and
(ix) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOxCHs, -SO2NH2, C1-3 alkyl, C1-3 haloalkyl, -OC1-3 alkyl, or -OC 1-3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(0=0)00^ alkyl, (iii) -(C=O)OH,
alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and
(vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, alkyl, or Ci-3 haloalkyl;, and
R6’ is selected from the group consisting of H, Ci^alkyl optionally substituted with 1-3 halogens, Phenyl, and -CH2-Phenyl, wherein Phenyl in both occurrences is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci .galkyl optionally substituted with 1-3 halogens, and (v) -OCi- 3alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of C1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC^j alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens,
alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2; in combination with an immune checkpoint inhibitor.
4. The method of claim 1 or 3, wherein said compound of formula II is of structural Formula Ila, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
Ila wherein
R1’ is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OCi-3alkyl optionally substituted with 1-3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -HC=NOH, (e) -(CH3)C=NOH, (f) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (g) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (i) -C(=O)NHR6’, (j) -CH=CH-Phenyl wherein -CH=CH- is
optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, (k) -CH^CF^-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and C1-2 alkyl optionally substituted with 1-3 F, (I) Phenyl, (m) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (n) -C^C-Phenyl, (0) -CH2-Phenyl, and (p) -CN, wherein the - CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and C1-2 alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi. 3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH, (iv) Ci.3alkyl optionally substituted with 1-3 halogens, (v) -OCi.3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R3’ is halogen;
R4 and R5 are each independently selected from the group consisting of:
(a) hydrogen:
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or Ci-3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7, and
(xiii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOXCH3, -SO2NH2, Ci.3 alkyl, Ci.3 haloalkyl, -OCi.3 alkyl, or -OC 1.3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents
independently selected from (i) halogen, (ii) -(0=0)00^3 alkyl, (iii) -(C=O)OH, (iv)
alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, or Ci-3 haloalkyl;
R6 is selected from the group consisting of H,
alkyl optionally substituted with 1-3 halogens, phenyl, or -CH2-phenyl, wherein phenyl is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(0=0)00^ alkyl optionally substituted with 1-3 halogens, (iii) -COOH, (iv) C1 3 alkyl optionally substituted with 1-3 halogens, and (v) -0C1 3 alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of C1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -0C1 3 alkyl, (iii) aryl, and (iv) heteroaryl, wherein wherein the aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2.
8. The method of claim 2 or 3, wherein said compound of Formula I is of structural Formula la, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
wherein:
R1 is selected from the group consisting of (a)
alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; and (f) -(C=O)NR5R6;
R4 is selected from the group consisting of (a) H; and (b) C1 3 alkyl optionally substituted with 1-5 halogens;
R5 and R6 are independently selected from the group consisting of C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC1-3 alkyl optionally substituted with 1-3 halogens; and
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i) halogen, (ii) C1 3 alkyl optionally substituted with 1-3 halogens, (iii) -OC1 3 alkyl optionally substituted with 1-3 halogens, (iv) -OH, and (vii) C1 3 hydroxyalkyl.
9. The method of claim 2 or 3, wherein said compound of formula I is of structural Formula lb, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
wherein:
R1 is selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1-3 alkyl optionally substituted with 1-3 halogens, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; and (f) -(C=O)NR5R6;
R4 is selected from the group consisting of (a) H; and (b) C1 3 alkyl optionally substituted with 1-5 halogens;
R5 and R6 are independently selected from the group consisting of
alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC^j alkyl optionally substituted with 1-3 halogens; and
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i) halogen, (ii) C1 3 alkyl optionally substituted with 1-3 halogens, (iii) -OC1 3 alkyl optionally substituted with 1-3 halogens, (iv) -OH, and (vii) C1 3 hydroxyalkyl.
10. The method of any one of claims 2, 8 and 9, wherein said compound of formula I is a compound selected from the following compounds:
11 . The method of any one of claims 1 to 10, wherein said immune checkpoint inhibitor is an a nti- PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or molecular inhibitors of these receptors.
12. The method of claim 11 , wherein said anti-PD-1 antibody is selected from the group consisting of nivolumab antibody, pembrolizumab antibody, pidilizumab antibody, cemiplimab antibody, dostarlimab antibody, JTX-4014 antibody, Spartalizumab antibody, Camrelizumab antibody, Sintilimab antibody, Tislelizumab antibody, Toripalimab antibody, INCMGA00012 antibody, AMP-224 antibody, AMP-514 antibody, RMP1-14 antibody or combinations thereof.
13. The method of claim 11 , wherein said anti-PDL-1 antibody is selected from the group consisting of B7-H1 antibody, BMS-936559 antibody, MPDL3280A (atezolizumab) antibody, MEDI-4736 antibody, MSB0010718C antibody, 10F-9G2 antibody, avelumab antibody, durvalumab antibody, or combinations thereof.
14. The method of claim 11 , wherein said anti-CTLA-4 antibody is selected from the group consisting of ipilimumab or tremelimumab or combinations thereof.
15. The method of any one of claims 1 to 14, wherein administration of said compound of structural
Formula I or structural Formula II is an intratumoral administration.
16. The method of any one of claims 1 to 14, wherein administration of said compound of structural Formula I or structural Formula II is an oral administration.
17. The method of any one of claims 1 to 14, wherein administration of said immune checkpoint inhibitor is a systemic administration, and intratumoral administration, or a combination thereof.
18. The method of any one of claims 1 to 14, wherein administration of said compound of structural Formula I or structural Formula II is an intratumoral administration and wherein administration of said immune checkpoint inhibitor is a systemic administration, an intratumoral administration, or a combination thereof, or wherein administration of said compound of structural Formula I is an intratumoral administration and wherein administration of said immune checkpoint inhibitor is a systemic administration, an intratumoral administration, or a combination thereof, or wherein administration of said compound of structural Formula I is an oral administration and wherein administration of said immune checkpoint inhibitor is a systemic administration, an intratumoral administration, or a combination thereof.
19. The method of any one of claims 1 to 18, wherein said compound of structural Formula I or structural Formula II is administered first, and said immune checkpoint inhibitor is administered second.
20. The method of any one of claims 1 to 18, wherein said cancer is a solid tumor, a prostate cancer, a breast cancer, a brain cancer, a glioma, a lung cancer, a salivary cancer, a stomach cancer, a thymic epithelial cancer, a thyroid cancer, an ovarian cancer, a multiple myeloma, a leukemia, a melanoma, a lymphoma, a gastric cancer, a kidney cancer, a pancreatic cancer, a bladder cancer, a colon cancer and a liver cancer.
21 . The use of a compound of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof, in combination with an immune checkpoint inhibitor, for the treatment of cancer:
Formula II
wherein X’ is selected from CH and N;
R1’ is selected from the group consisting of (a) Ci^alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OC salkyl optionally substituted with 1- 3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -CN, (e) -HC=NOH, (f) -(CH3)C=NOH, (g) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens (i) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (j) -C(=O)NHR6’, (k) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, (I) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and Ci -2alkyl optionally substituted with 1-3 F, (m) Phenyl, (n) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (0) -C^C-Phenyl, and (p) -CH2-Phenyl, wherein the -CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and Ci^alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen,
(ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci -3alkyl optionally substituted with 1-3 halogens, (v) -OCi-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
R4’ and R5’ are each independently selected from the group consisting of:
(a) hydrogen;
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or C1.3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7and
(ix) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOXCH3, -SO2NH2, Ci.3 alkyl, Ci.3 haloalkyl, -OCi.3 alkyl, or -OC 1.3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1.3 alkyl, (iii) -(C=O)OH,
alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, or Ci-3 haloalkyl;, and
R6’ is selected from the group consisting of H, Ci-3alkyl optionally substituted with 1-3 halogens, Phenyl, and -CH2-Phenyl, wherein Phenyl in both occurrences is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=0)0Ci-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci -3alkyl optionally substituted with 1-3 halogens, and (v) -OCi- 3alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of C1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC^j alkyl, (iv) aryl, and (v) heteroaryl, wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C^ alkyl, Ci-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2.
22. The use of a compound of structural Formula I, or pharmaceutically acceptable salts thereof, and stereoisomers thereof in combination with an immune checkpoint inhibitor for the treatment of cancer:
Formula I wherein:
X is selected from CH and N;
R1 is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, -SO^.3 alkyl, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; (f) -(C=O)NR5R6; and (g) aryl or heteroaryl wherein the aryl and heteroaryl group itself may be optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C^jOC^ alkyl optionally substituted with 1-3 halogens, (iii) -COOH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, (vii) -CN, and (viii) -SO2NH2;
R2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
R4 is selected from the group consisting of (a) H; (b) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -0C1-3 alkyl optionally substituted with 1- 3 halogens, -SOXC1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C^ alkyl or C1.3 haloalkyl;
R5 and R6 are independently selected from the group consisting of (a)
alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC^ alkyl optionally substituted with 1-3 halogens, -SOXC1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C1 3 alkyl or C1 3 haloalkyl;
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with 1-3 groups independently selected from (i) halogen, (ii) -(0=0)00^ alkyl, (iii) -(C=O)OH (iv) C^ alkyl optionally substituted with 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, (vii) C1 3 hydroxyalkyl, (viii) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C 3 alkyl or C1-3 haloalkyl; and x is an integer from 0 to 2.
23. The use of a combination of a compound of structural Formula I and of structural Formula II, or pharmaceutically acceptable salts thereof, and stereoisomers thereof in combination with an immune checkpoint inhibitor for the treatment of cancer:
Formula I wherein:
X is selected from CH and N;
R1 is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, -SO.C.^ alkyl, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; (f) -(C=O)NR5R6; and (g) aryl or heteroaryl wherein the aryl and heteroaryl group itself may be optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C^jOC^ alkyl optionally substituted with 1-3 halogens, (iii) -COOH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -0C1 3 alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, (vii) -CN, and (viii) -SO2NH2;
R2 and 3 are independently selected from the group consisting of (a) halogen; (b) difluoromethylphosphonic acid;
R4 is selected from the group consisting of (a) H; (b) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -0C1 3 alkyl optionally substituted with 1- 3 halogens, -SOXC1.3 alkyl, and -CN; (d) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C1 3 alkyl or C1.3 aloalkyl;
R5 and R6 are independently selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -0C1 3 alkyl optionally substituted with 1-3 halogens, -SOXC1.3 alkyl, and -CN; (b) aryl or heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1 -3 halogens, C1 3 alkyl or C1 3 haloalkyl;
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with 1-3 groups independently selected from (i) halogen, (ii) -(0=0)00^ alkyl, (iii) -(C=O)OH (iv) C1 3 alkyl optionally substituted with 1-3 halogens, (v) -0C1.3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, (vii) C^ hydroxyalkyl, (viii) aryl or
heteroaryl wherein the aryl or heteroaryl group itself may be optionally substituted by 1-3 halogens, C1
R1’ is selected from the group consisting of (a) Ci-3alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OCi-3alkyl optionally substituted with 1- 3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -CN, (e) -HC=NOH, (f) -(CH3)C=NOH, (g) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens (i) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (j) -C(=O)NHR6’, (k) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, (I) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, (m) Phenyl, (n) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (0) -C^C-Phenyl, and (p) -CH2-Phenyl, wherein the -CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and Ci-2alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Cvsalkyl optionally substituted with 1-3 halogens, (v) -OCi-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R2’ and R4’ are independently selected from H, halogen, -CH3, -CF3, -OCH3, and -OCF3;
R3’ is halogen, wherein said halogen is bonded to the fused aromatic ring of Formula II at a position ortho to the -CF2PO(OR5’)2 group,
R4’ and R5’ are each independently selected from the group consisting of:
(a) hydrogen;
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C-|-3 alkyl, or C1-3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7and
(ix) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOxCHs, -SO2NH2, C1-3 alkyl, C1-3 haloalkyl, -OC1-3 alkyl, or -OC 1-3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl, (iii) -(C=O)OH, (iv) C1 3 alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -OC1-3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1 3 alkyl, or Ci-3 haloalkyl; and
R6’ is selected from the group consisting of H, Ci^alkyl optionally substituted with 1-3 halogens, Phenyl, and -CH2-Phenyl, wherein Phenyl in both occurrences is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi-3alkyl optionally substituted with 1-3 halogens, (iii) -C(=O)OH (iv) Ci -3alkyl optionally substituted with 1-3 halogens, and (v) -OCi- 3alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of
alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) hydroxy, (iii) -OC1-3 alkyl, (iv) aryl, and (v) heteroaryl,
wherein wherein aryl and heteroaryl are optionally substituted with 1-3 halogens,
alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COCH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or 1-5 fluorines; and x is 0, 1 , or 2.
24. The use of claim 21 or 23, wherein said compound of formula II is of structural Formula Ila, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
Ila wherein
R1’ is selected from the group consisting of (a) C1-3 alkyl optionally substituted with 1-3 halogens and optionally with one group selected from -OH, -OCi-3alkyl optionally substituted with 1-3 halogens, -SOxCi-3alkyl, and -CN, (b) -C(=O)H, (c) -C(=O)Ci-3alkyl optionally substituted with 1-3 halogens, (d) -HC=NOH, (e) -(CH3)C=NOH, (f) -HC=NOCi-3alkyl optionally substituted with 1-3 halogens, (g) -(CH3)C=NOCi-3alkyl optionally substituted with 1-3 halogens, (h) -C(=O)OCi.3alkyl optionally substituted with 1-3 halogens, (i) -C(=O)NHR6’, (j) -CH=CH-Phenyl wherein -CH=CH- is optionally substituted with 1-2 substituents independently selected from halogen and Ci.2alkyl optionally substituted with 1-3 F, (k) -CH2CH2-Phenyl wherein -CH2CH2- is optionally substituted with 1-4 substituents independently selected from halogen and C1-2 alkyl optionally substituted with 1-3 F, (I) Phenyl, (m) -HET-Phenyl, wherein HET is a 5- or 6-membered heteroaromatic ring containing 1-3 heteroatoms selected from O, N and S, (n) -C^C-Phenyl, (0) -CH2-Phenyl, and (p) -CN, wherein the - CH2- group of -CH2-Phenyl is optionally substituted with 1-2 substituents independently selected from halogen and C1-2 alkyl optionally substituted with 1-3 F, wherein Phenyl and HET in all occurrences are optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -C(=O)OCi. 3a Iky I optionally substituted with 1-3 halogens, (iii) -C(=O)OH, (iv) Ci-salkyl optionally substituted with 1-3 halogens, (v) -OCi-3alkyl optionally substituted with 1-3 halogens, (vi) -SOxMe, and (vii) -SO2NH2;
R3’ is halogen;
R4 and R5 are each independently selected from the group consisting of:
(a) hydrogen:
(b) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C-|-3 alkyl, or C1.3 haloalkyl; and
(c) -(CRaRb)i-2 substituted with one to two substituents independently selected from
(i) -(C=O)OR7,
(ii) -(C=O)NHR7,
(iii) -(C=O)N(R7)2,
(iv) -(C=O)NH2,
(v) -OR7,
(vi) -O(C=O)R7,
(vii) -O(C=O)OR7,
(viii) -O(C=O)NHR7,
(ix) -O(C=O)N(R7)2,
(x) -O(C=O)NH2,
(xi) -SO2NH2,
(xii) -SOXCH3,
(viii) -S(C=O)R7, and
(xiii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, -CN, -SOxCHs, -SO2NH2, C1-3 alkyl, C1-3 haloalkyl, -OC1-3 alkyl, or -OC 1-3 haloalkyl; or R4’ and R5’ together with the phosphorus atom and the two oxygen atoms to which they are attached form a 5- to 7-membered ring optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl, (iii) -(C=O)OH, (iv) C1 3 alkyl optionally substituted with hydroxy or 1-3 halogens, (v) -OC1-3 alkyl optionally substituted with 1-3 halogens, (vi) -OH, and (vii) aryl or heteroaryl wherein aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, or Ci-3 haloalkyl;
R6 is selected from the group consisting of H, C1 3 alkyl optionally substituted with 1-3 halogens, phenyl, or -CH2-phenyl, wherein phenyl is optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -(C=O)OC1 3 alkyl optionally substituted with 1-3 halogens, (iii) -COOH, (iv) C1 3 alkyl optionally substituted with 1-3 halogens, and (v) -OC1 3 alkyl optionally substituted with 1-3 halogens;
R7 is selected from the group consisting of C1 6 alkyl optionally substituted with 1-3 substituents independently selected from (i) halogen, (ii) -OC1-3 alkyl, (iii) aryl, and (iv) heteroaryl,
wherein wherein the aryl and heteroaryl are optionally substituted with 1-3 halogens, C1-3 alkyl, C1-3 haloalkyl, -CN, -SOXCH3, -SO2NH2, -COOH, and -OC^ alkyl;
Ra and Rb are each independently hydrogen or C1-4 alkyl optionally substituted with hydroxy or
1-5 fluorines; and x is 0, 1 , or 2.
28. The use of claim 22 or 23, wherein said compound of Formula I is of structural Formula la, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
wherein:
R1 is selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; and (f) -(C=O)NR5R6;
R4 is selected from the group consisting of (a) H; and (b) C1 3 alkyl optionally substituted with 1-5 halogens;
R5 and R6 are independently selected from the group consisting of
alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC^j alkyl optionally substituted with 1-3 halogens; and
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i)
halogen, (ii) alkyl optionally substituted with 1-3 halogens, (iii) -OC^ alkyl optionally substituted with 1-3 halogens, (iv) -OH, and (vii)
hydroxyalkyl.
29. The use of claim 22 or 23, wherein said compound of formula I is of structural Formula lb, or a pharmaceutically acceptable salts thereof, and stereoisomers thereof:
wherein:
R1 is selected from the group consisting of (a) C1 3 alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, -OC1 3 alkyl optionally substituted with 1-3 halogens, and -CN; (b) -(C=O)R4; (c) -CN; (d) -(C=O)OR4; (e) -(C=O)NHR4; and (f) -(C=O)NR5R6;
R4 is selected from the group consisting of (a) H; and (b)
alkyl optionally substituted with 1-5 halogens;
R5 and R6 are independently selected from the group consisting of
alkyl optionally substituted with 1-5 halogens and optionally with one group selected from -OH, and -OC1 3 alkyl optionally substituted with 1-3 halogens; and
R5 and R6, together with the nitrogen atom to which they are attached may be joined to form a 5- to 7-membered ring, which may be substituted with a 1-3 groups independently selected from (i) halogen, (ii) C1 3 alkyl optionally substituted with 1-3 halogens, (iii) -OC1 3 alkyl optionally substituted with 1-3 halogens, (iv) -OH, and (vii)
hydroxyalkyl.
31 . The use of any one of claims 21 to 30, wherein said immune checkpoint inhibitor is an anti-PD- 1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or molecular inhibitors of these receptors.
32. The use of claim 31 , wherein said anti-PD-1 antibody is selected from the group consisting of nivolumab antibody, pembrolizumab antibody, pidilizumab antibody, cemiplimab antibody, dostarlimab antibody, JTX-4014 antibody, Spartalizumab antibody, Camrelizumab antibody, Sintilimab antibody, Tislelizumab antibody, Toripalimab antibody, INCMGA00012 antibody, AMP-224 antibody, AMP-514 antibody, RMP1-14 antibody or combinations thereof.
33. The use of claim 31 , wherein said anti-PDL-1 antibody is selected from the group consisting of B7-H1 antibody, BMS-936559 antibody, MPDL3280A (atezolizumab) antibody, MEDI-4736 antibody, MSB0010718C antibody, 10F-9G2 antibody, avelumab antibody, durvalumab antibody, or combinations thereof.
34. The use of claim 31 , wherein said anti-CTLA-4 antibody is selected from the group consisting of ipilimumab or tremelimumab or combinations thereof.
35. The use of any one of claims 21 to 34, wherein use of said compound of structural Formula I or structural Formula II is an intratumoral use.
36. The use of any one of claims 21 to 34, wherein use of said compound of structural Formula I or structural Formula II is an oral use.
37. The use of any one of claims 21 to 34, wherein use of said immune checkpoint inhibitor is a systemic use, and intratumoral use, or a combination thereof.
38. The use of any one of claims 21 to 34, wherein use of said compound of structural Formula I or structural Formula II is an intratumoral use and wherein use of said immune checkpoint inhibitor is a systemic use, an intratumoral use, or a combination thereof, or wherein use of said compound of structural Formula I is an intratumoral use and wherein use of said immune checkpoint inhibitor is a systemic use, an intratumoral use, or a combination thereof, or wherein use of said compound of structural Formula I is an oral use and wherein use of said immune checkpoint inhibitor is a systemic use, an intratumoral use, or a combination thereof.
39. The use of any one of claims 21 to 38, wherein said compound of structural Formula I or structural Formula II is administered first, and said immune checkpoint inhibitor is administered second.
40. The use of any one of claims 21 to 38, wherein said cancer is a solid tumor, a prostate cancer, a breast cancer, a brain cancer, a glioma, a lung cancer, a salivary cancer, a stomach cancer, a thymic epithelial cancer, a thyroid cancer, an ovarian cancer, a multiple myeloma, a leukemia, a melanoma, a lymphoma, a gastric cancer, a kidney cancer, a pancreatic cancer, a bladder cancer, a colon cancer and a liver cancer.
41. The method of any one of claims 1 to 20, or the use of any one of claims 21 to 40, further comprising monitoring the activity of the compound of structural Formula I, structural Formula II or both structural Formula I and structural Formula II.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263343662P | 2022-05-19 | 2022-05-19 | |
US63/343,662 | 2022-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023220833A1 true WO2023220833A1 (en) | 2023-11-23 |
Family
ID=88834259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2023/050693 WO2023220833A1 (en) | 2022-05-19 | 2023-05-19 | Combined inhibition of tyrosine phosphatases tcptp and ptp1b and pd-1 blockage immunotherapy in the treatment of cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023220833A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168815B2 (en) * | 2007-01-26 | 2012-05-01 | Kaneq Pharma Inc. | Fused aromatic PTP-1B inhibitors |
WO2013155600A1 (en) * | 2012-04-16 | 2013-10-24 | Kaneq Pharma | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
-
2023
- 2023-05-19 WO PCT/CA2023/050693 patent/WO2023220833A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8168815B2 (en) * | 2007-01-26 | 2012-05-01 | Kaneq Pharma Inc. | Fused aromatic PTP-1B inhibitors |
WO2013155600A1 (en) * | 2012-04-16 | 2013-10-24 | Kaneq Pharma | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
US20150057220A1 (en) * | 2012-04-16 | 2015-02-26 | Kaneq Pharma Inc. | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Riella et al. | Role of the PD-1 pathway in the immune response | |
Gadó et al. | Role of interleukin‐6 in the pathogenesis of multiple myeloma | |
Cano et al. | Introduction to T and B lymphocytes | |
Seder et al. | The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. | |
Sawada et al. | Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. | |
Clouthier et al. | Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection | |
US11597739B2 (en) | Enhancing CD8+ T cells for adoptive T cell therapy by inhibiting PTPN1 (PTP1B) and PTPN2 (TC-PTP) | |
JP5798919B2 (en) | Compositions and methods of use of PD-1 antagonists | |
WO2001015732A1 (en) | Remedies for immunological diseases | |
Plum et al. | Influence of TGF-beta on murine thymocyte development in fetal thymus organ culture. | |
VERBANAC et al. | A ROLE FOR TRANSFORMING GROWTH FACTOR-BETA IN THE VETO MECHANISM IN TRANSPLANT TOLERANCE1, 2 | |
KR20220118532A (en) | Novel Mesothelin Specific Chimeric Antigen Receptors (CAR) for Solid Tumors Cancer Immunotherapy | |
TW202346321A (en) | Il-7r-alpha-gamma immunoglobulin fusion proteins | |
Schultz et al. | T helper cell membranes promote IL-4-independent expression of germ-line C gamma 1 transcripts in B cells. | |
Yamana et al. | Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+ T cells from patients with rheumatoid arthritis | |
Wolf et al. | The kinase inhibitor imatinib-an immunosuppressive drug? | |
Tanaka et al. | In utero treatment with monoclonal antibody to IL-2 receptor β-chain completely abrogates development of Thy-1+ dendritic epidermal cells | |
WO2023220833A1 (en) | Combined inhibition of tyrosine phosphatases tcptp and ptp1b and pd-1 blockage immunotherapy in the treatment of cancer | |
Cui et al. | CD30 plays a role in T‐dependent immune response and T cell proliferation | |
TW202320817A (en) | Methods and compositions for treating cancer | |
Weyand et al. | Lymphoid microstructures in rheumatoid synovitis | |
Petersone et al. | T-cell help in the germinal center: homing in on the role of IL-21 | |
Zhang et al. | Cancer immunity by tissue‐resident type 1 innate lymphoid cells and killer innate‐like T cells | |
Mueller et al. | Subset of CD4+ T cell clones expressing IL-3 receptor alpha-chains uses IL-3 as a cofactor in autocrine growth. | |
WO2023077242A1 (en) | Phosphatase inhibitors as nk cells modulators for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23806488 Country of ref document: EP Kind code of ref document: A1 |